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ABSTRACT 
Background: Sepsis with multi-organ failure has an unacceptably high mortality rate of 25-
30% despite the use of antibiotics and modern intensive care. Attenuating the multi-organ 
failure and finding new biomarkers for early detection of septic shock would be of high 
clinical relevance in order to improve outcome. 
Aim: The aim of this thesis was to study if inhaled nitric oxide (iNO) in combination with 
steroids could attenuate multi-organ failure in a porcine model of endotoxemia. We further 
aimed to investigate the dynamics of circulating citrullinated histone H3 (H3Cit), a recently 
proposed biomarker in sepsis, in a human model of endotoxemia. Since microvesicles (MVs) 
have been shown to be elevated in sepsis, a further objective of this thesis was to investigate 
whether H3Cit could be detected bound to MVs. 
Methods: A randomized controlled trial (RCT) with 30 domestic piglets exposed to 
lipopolysaccharide (LPS)-alone, LPS + iNO, LPS + IV steroid, LPS + iNO + IV steroid or 
anesthesia only (Control) was conducted in paper I. Various biomarkers were measured at 
endpoint in order to evaluate organ function after 30 hrs of endotoxic shock. In paper II, an 
ELISA-based assay quantifying plasma H3Cit was developed and methodologically validated 
in accordance to recommended ELISA validation requirements. This ELISA, as well as a 
flow cytometric assay quantifying MV-bound H3Cit, was used in plasma samples at baseline 
and then 2, 4 and 7 hrs after LPS-injection in a placebo controlled RCT including 22 healthy 
volunteers in Paper III. 
Results: LPS + iNO+ IV steroid tended to require less norepinephrine and were significantly 
less acidotic (p < 0.05) compared to LPS-only in the porcine model of endotoxemia. No 
significant differences could, however, be detected in other clinical variables. Circulating 
H3Cit, quantified by the ELISA assay, which was validated with high specificity, precision 
and stability, rose significantly after LPS injection in the human model of endotoxemia. 
Similar elevations were seen when quantifying H3Cit-bearing neutrophil- and platelet derived 
MVs. 
Conclusions: Our data suggest that combined therapy with iNO and IV steroid is at least 
partially, protective after experimental LPS infusion. We furthermore show that circulating 
H3Cit, quantified by two distinct methods, is elevated after experimental LPS injection, 
suggesting that H3Cit may be a novel biomarker even in sepsis. Our data also show that 
H3Cit can be detected bound to MVs, proposing a novel mechanism by which H3Cit can be 
transported throughout the vasculature.  
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1 INTRODUCTION 
1.1 MEDICAL PROBLEM/BACKGROUND 
The mortality in severe sepsis and septic shock is still unacceptably high, although it tends to 
decrease from around 30-80% to 20-30% through improved bundles of early interventions 
and advances in training and surveillance [2-6]. Patients with septic shock and multi-organ 
failure (MOF) account for the highest mortality [4, 7]. Clearly, antibiotics are of vital 
importance in order to eliminate bacteria that constitute the initial cause of septic shock. 
Nevertheless, up to date there are no documented treatments in attenuating MOF while the 
antibiotics exerts its full effect. Therefore, treatments in order to reduce MOF are stressed in 
order to decrease mortality resulting from sepsis.  
The fundamental theory that sepsis is an effect of uncontrolled inflammation has lately been 
disputed. Instead, the dynamics of the immune profile have been urged to be of importance, 
going from a proinflammatory state with e.g. a massive cytokine response initially, to a rather 
immunosuppressed condition at a later stage [8-11]. Hence, not considering these different 
immune phases could be one cause of some disappointing results historically in trying to 
inhibit the immune response [8], by e.g. an early cytokine activation administering anti-
Tumour Necrosis Factor α (anti-TNFα) or anti-Interleukin 1 (anti-IL1) [12], as well as 
corticosteroids of 30 mg/kg [13] and anti- endotoxin antibodies [14].   
Consequently, it is of vital importance to understand the pathogeneses of sepsis, which can 
lead us towards useful biomarkers and possible targeted therapies that could attenuate the 
multi-organ failure connected with septic shock. Further, more useful future biomarkers 
should enable the differentiation of patients at risk for more severe infections and could also 
be of help in initiating correct treatment as well as facilitating prediction of outcome.  
A biomarker can be defined as a characteristic by which a pathophysiologic process might be 
identified [15]. Up to date several different biomarkers for sepsis have been studied but their 
clinical effectiveness in predicting sepsis remains elusive [15, 16]. The currently updated 
guidelines from “survival sepsis campaign” [17] discuss minor use of only one biomarker, 
procalcitonin, for help in guiding antibiotic treatment, even though both elevated C Reactive 
Protein (CRP) and in particular lactate, are widely used tools in order to identify and predict 
sepsis diagnosis and its outcome in clinical practice [1, 18, 19]. Hence, the research about 
biomarkers in sepsis is still at its beginning and should be warranted in order to ameliorate the 
outcome of this lethal disease. 
 
1.2 DEFINITION OF SEPSIS 
1.2.1 Classic definitions  
For many years, sepsis has been considered a stepwise progression reflecting an exaggerated 
host response to inflammation [20]. The proposed definitions are listed below: 
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1.2.1.1 Systemic Inflammatory Response Syndrome 
The first stage is the systemic inflammatory response syndrome (SIRS). SIRS is considered 
an inflammatory condition that may harm the patient. Triggers to SIRS can be infection, 
trauma, pancreatitis, burns and different kinds of shock.  
SIRS is apparent when > 2 of the signs listed below are apparent:  
• Temperature > 38 or < 36°C,  
• Heart rate > 90 beats per minute   
• Respiratory rate > 20 per minute / pCO2 < 4,2 kPa,  
• White Blood Cell (WBC) count  > 12 x109 or < 4 x 109/L or > 10% immature 
neutrophils “bands”/forms  
1.2.1.2 Sepsis 
Sepsis is defined as simultaneous occurrence of SIRS + infection 
1.2.1.3 Severe sepsis 
Sepsis+ organ dysfunction (e.g. signs of respiratory failure, hypotension and hypoperfusion). 
1.2.1.4 Septic shock 
When severe sepsis goes with refractory hypotension, meaning an inadequate response to 
“adequate” amount of fluids, septic shock is apparent. 
In the revised definitions of sepsis from 2001, Levy et al concluded that even if the traditional 
classification based on SIRS might remain helpful to clinicians and researchers, the concept 
is overly sensitive and non-specific. Therefore, the authors presented an expanded list of 
symptoms and signs of sepsis (e.g. oliguria, elevated creatinine, lactate > 1) and also 
concluded that “the use of biomarkers for diagnosing sepsis is premature” [19]. 
1.2.2 New proposal for the sepsis definition 
Recently the SIRS-based definitions defined by Bone et al have been challenged [1]. The 
proposition called “Sepsis-3” is a new definition of sepsis: “Sepsis is defined as life-
threatening organ dysfunction caused by a dysregulated host response to infection". The 
diagnostic criteria of Sepsis-3 is based on the Sequential [Sepsis-related] Organ Failure 
Assessment (SOFA) [21], composed of a scoring system from six organ functions 
(cardiovascular, respiratory, hepatic, renal, coagulation and neurological), graded in relation 
to the degree of the dysfunction. By this definition, the notion of severe sepsis is redundant. 
Even the term SIRS is obliterated due to its unspecific nature. In Sweden, a consensus group 
recently decided to use the new definitions and diagnostic criteria for sepsis as well as for 
septic shock. However the use of the new screening tool, “quick-SOFA”, proposed by Sepsis-
3, will not be applied in Sweden, until prospectively validated [22].  
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1.3 THE IMMUNE SYSTEM 
The immune system is a complex system of biological processes and structures within an 
organism that defends it against disease. In order to function accurately, the immune system 
must discover a variety of pathogens and differentiate them from endogenous healthy tissue.  
The immune system can be sub-classified or sub-divided into the innate- (unspecific/native) 
and the adaptive (specific) immune system that is acquired later in life, as opposed to the 
innate immunity [23]. Included in the adaptive immune system is a so-called, immunological 
memory [24]. It comprises antibodies from B-lymphocytes that eliminate or neutralize 
microbial toxins and microbes, existing outside the host cells, constituting the humoral 
immunity. Furthermore, T-cells that constitute another part of the adaptive immune system, 
act by inducing apoptosis for infected cells and is called “cell mediated immunity”. 
This thesis will however, focus mainly on the innate immune system, with a special interest 
in a recently described subgroup of components called neutrophil extracellular traps (NETs). 
1.3.1 The innate immune system 
The innate immune system exists from birth and serves as a first line defense when the body 
is infected by a pathogen. Unlike the adaptive immune system, it cannot adapt to a certain 
pathogen. Nevertheless, the innate system mobilizes quicker than the adaptive defense. 
The innate immune system comprises of neutrophils and monocytes, acting by phagocytosis 
(ingestion) and destruction of microbes; natural killer (NK) cells that kill pathogen-infected 
cells; endothelial cells; monocytes that together with dendritic cells serve as antigen-
presenting cells, thereby stimulating the subsequent adaptive immune response [23]. When a 
monocyte exits from the vascular space it develops into a macrophage. Macrophages 
phagocyte invading pathogens, but can also secrete cytokines, which recruit additional 
immune cells to the infected area [23].  
An overview of the innate- and adaptive immune system is presented in figure 1.  
 
 
Definitions of sepsis and septic shock according to Sepsis-3 [1] 
• Sepsis: Infection+ acute change in total SOFA score >= 2 points. 
• Septic shock: Infection + persisting hypotension requiring vasopressors 
to maintain MAP > 65 mm Hg + serum lactate level > 2 mmol/L (18 
mg/dL) despite adequate volume resuscitation. 
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Figure 1. Overview of the human immune response. Reprinted from “Understanding 
Modern Vaccines: Perspectives in Vaccinology” Leo et al (2011); J. Pervac; 1(1) 25-59 with 
permission by Elsevier through CC BY-NC-ND 3.0 license. © 2011 Elsevier B.V. 
The innate immune system, the first line of defense, comprises of several immune cells. 
Granulocytes are subdivided into neutrophils, basophiles and eosinophils. 1) After activation 
of the innate immune system, granulocytes together with monocytes and their extravascular 
form, macrophages, ingest/phagocyte pathogen-infected cells, which are subsequently killed 
by Natural killer cells (NK). 2) Dendritic cells mature into antigen-presenting cells (APC) in 
presence of a pathogen and serve as an important link in triggering the adaptive immune 
system that are developed later in life. Activation of the adaptive immune system includes 3) 
secretion of cytokines by the CD4+ T-helper cells that also 4) stimulate B-cells to secrete 
antibodies. 5) Antibodies can neutralize antigens and 6) enhance functionality in innate 
immune cells. Further, 7) CD8+cytotoxic T-cells are activated 8) inducing apoptosis in 
infected cells by. All together, these actions lead to efficient clearance of pathogen by among 
other things, production of anti-bodies. 
APC = Antigen presenting cell; CD = cluster of differentiation 
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1.3.1.1 Activation of the innate immune system by PAMPs and DAMPs 
The ability of the macrophage to promptly fight infections is due to receptors in their cell 
membranes, recognizing foreign components from e.g. bacteria. These pathogen components 
are often called “pathogen-associated molecular patterns” (PAMPs) [25]. Lipopolysaccharide 
(LPS) incorporated in the bacterial wall of Escherichia coli (E. coli) is an example of a 
PAMP. PAMPs also include foreign molecules released from bacterial lysis, such as bacterial 
DNA fragments and heat-shock proteins.  
The activation of the innate immune defense could also arise after recognition of endogenous 
molecules released during cell death or cell injury, known as damage-associated molecular 
patterns (DAMPs). One example of DAMPs is High Mobility Box Protein 1 (HMGB1). 
HMGB1 is a nuclear protein that translocates from the nucleus to the extracellular space in 
response to inflammation, thereby executing downstream cytokine stimulation [26]. 
1.3.1.2 Toll-like receptors 
Receptors binding/recognizing DAMPs and PAMPs are called pattern recognition receptors 
and include toll-like receptors (TLRs) [27-29]. In mice and humans there are 10 known TLRs 
[29]. Stimulation of TLR leads to induction of inflammatory cytokines and antimicrobial 
genes. Furthermore, activation of TLRs generates dendritic cell maturation that results in 
increased antigen-presenting capacity. Hence, microbial detection by TLRs not only triggers 
the innate immune system, but also helps guiding the adaptive immune responses. Andonegui 
et al [30] showed that platelets present the TLR4, thus playing a role in the inflammatory 
response. Moreover, the cytokine response generated from translocation of HMGB1 to the 
extracellular space, is mediated by the TLR4 [26]. 
1.3.1.3 DAMPs as biomarkers 
Several DAMPs have been evaluated as biomarkers in sepsis. In addition to HMGB1, cell- 
free DNA (cfDNA) has been proposed as a potential biomarker of use. CfDNA is defined as 
DNA strands, normally enclosed within the cell nucleus, circulating freely in the blood 
stream. Indeed cfDNA has been shown to be elevated in e.g. apoptosis and necrosis [31, 32]. 
Moreover cfDNA has been used as an indirect marker of another molecule of the innate 
immune system: Neutrophil Extra Cellular Traps (NETs).  
 
 
 
 
 
PAMPs: Patterns on pathogen recognized by the immune system 
(e.g. LPS, bacterial DNA fragments) 
DAMPs: Endogenous molecules released (e.g. cfDNA, HMGB-1) 
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1.3.2 Neutrophil extracellular traps (NETs) 
Neutrophils are the most abundant white blood cells, and their antimicrobial activities by 
phagocytosis and degranulation are well defined. Interestingly, a third antimicrobial 
mechanism was described just over a decade ago [33], in which the neutrophils release their 
nuclear content in the form of web-like structures consisting of DNA strands, coated with 
histones and granular proteases, referred to as neutrophil extracellular traps, NETs.  
The mechanisms by which neutrophils release NETs are not fully understood, but the 
assembly of Nikotinamid-Adenin-Dinukleotidfosfat phosphate (NADPH) oxidase upon 
neutrophil activation, leading to the production of reactive oxygen species (ROS) and the 
activation of the enzyme peptidylarginine deiminase 4 (PAD4) has been shown to play a 
central role. Upon activation, PAD4 enters the nucleus and converts positively charged 
arginine residues to uncharged citrulline residues (i.e. citrullination) on histone H3 (referred 
to as H3Cit), thereby reducing its positive charge. The production of ROS also triggers the 
leakage of granular proteases, such as neutrophil elastase (NE) and myeloperoxidase (MPO), 
which move to the nucleus and cleave histones. Citrullination and cleavage of histones result 
in chromatin decondensation, the initial step of NETosis. Decondensated chromatin coated 
with the antimicrobial granular proteases (i.e. NETs), are subsequently extruded into the 
extracellular space, where they are shown to kill microbes both by physical entrapment, as 
well as by the high concentration of antimicrobial proteases [33]. ROS-independent NETosis 
has also been described [34]. 
 
 
Figure 2. NETosis. Reproduced with permission from Charlotte Thålin, MD, PhD. 
A) Nucleosomes are tightly packed DNA-strands coiled around a core of 8 histones, and 
organized into condensed chromatin in the nucleus. B) Peptidylarginine deaminase 4 (PAD4) 
is an enzyme primarily expressed in neutrophils. Upon activation of the neutrophil, PAD4 
and granular proteases initiate NETosis, by translocating into the nucleus where C) PAD4 
citrullinates the arginine residue of histone H3 and the proteases cleave the histones, both 
actions resulting in chromatin decondensation. D) Finally, the decondensed chromatin, coated 
with antimicrobial proteases, is extruded into the extracellular space. 
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1.3.2.1 Suicidal and vital NETosis 
The schematic in figure 2 illustrates the ROS-dependent and “lytic” or “suicidal” NETosis. 
This process, necessitates lytic cell death of the neutrophil and takes up to 2-3 hours if the 
neutrophil is directly stimulated by the pathogen [35].  
A different form of NETosis, “vital NETosis” has also been reported [36]. Vital NETosis 
involves budding of microvesicles transported into the extracellular space, where they rupture 
and release NETs. This process takes 5-60 min, does not require neutrophil lysis and is ROS-
independent. Notably, vital NETosis preserves neutrophil function including the recruitment 
cascade, phagocytosis, chemotaxis and microbial killing [36]. 
1.3.2.2 Triggers for NETosis 
NETosis can be triggered in several ways, e.g. by intracellular oxidative stress, 
Staphylococcus aureus [36, 37], fungi and E. coli, and LPS [38]. However, only a portion of a 
neutrophil population will release NETs in response to stimuli [39]. Platelets also have a role 
in NET formation by binding LPS via TLR4 on their surface and presenting LPS to the 
neutrophil, initiating NETosis in the smallest vessels of lung and liver. NETosis induced by 
platelet-LPS interaction only takes minutes [40].  
1.3.2.3 Clinical role of NETs 
Neutrophils use three main strategies in the defense towards microbes: phagocytosis (within 
10 min and pose no harm to the host), degranulation (within 30 min, certain damage to the 
host), and NET formation (within 10 min-3 hrs depending on NETosis trigger.) NET are a 
strategy to kill and trap bacteria within the NET, thus trying to shelter the host from 
neutrophil granualae that could cause damage [35].  
Elevated plasma concentrations of NETs have been noted in both endotoxemia [41] and 
sepsis [42], where they are thought to play an important role in the early pathogen defense, 
possibly inhibiting dissemination of local infection. On the other hand, excessive formation 
and insufficient regulation of NETs may be harmful to the host. For example, NETs could 
promote inflammation and occlude capillaries which impair the micro-circulation [43]. 
Histones released from neutrophils have also been shown to harm organs/tissues [42, 44]. 
Indeed, high levels of NETs seem to be correlated to the severity of sepsis and multi-organ 
failure [45]. Therefore, it has been discussed about the possible use of NETs, or its 
components, as predictors of multi-organ failure and mortality in sepsis. Up to date, it is not 
known at what point NETs become detrimental, but the fine-tuning of NETosis throughout 
the septic immune response, could be a focus of development for new NET-targeted sepsis- 
therapies. 
Even though NETs are implicated in the defense of microbes and consequently have a role in 
infection, NETs have also been associated with several non-infectious and sterile conditions 
such as thrombosis [46], systemic lupus erythematous [47], acute lung injury [48, 49], small 
vessel vasculitis [50], diabetes [51] and cystic fibrosis [52]. Recently, NETs have also been 
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proposed to play a role in tumor progression [53], metastatic spread [54, 55] and cancer-
associated thrombosis [56, 57]. Notably, NETs have been shown to accumulate in peripheral 
blood vessels and impair vascular function in tumor-bearing mice [58] and markers of NETs 
have been detected in widespread microthrombi in cancer patients, possibly contributing to 
MOF, as has been shown in sepsis [45]. 
1.3.2.4 Methods of measuring NETs 
NETs can be visualized by histology utilizing light- and electron microscopy [59]. However, 
microscopy comes with two major limitations: the lack of objectivity and the lack of 
quantification [60]. Quantification of surrogate NET markers, such as the NET-associated 
granular proteases NE and MPO and cfDNA, by commercially available enzyme-linked 
immunosorbent assays (ELISAs) have therefore been used to measure the levels of NETs in 
plasma. Yet, results from the methods mentioned may have to be interpreted with caution 
since cfDNA can arise from events other than NETosis [61]. Also, MPO and NE can exist 
from neutrophil activation not resulting in NETosis [62, 63]. In the context of biomarkers in 
sepsis, increasing attention has revolved around the NET-specific component citrullinated 
histone H3 (H3Cit), being a more specific marker for NETosis than e.g. cfDNA or the 
granular proteases. However, until recently, authors have detected H3Cit mainly by Western 
blot [64] in lack of a validated ELISA for the quantification of plasma H3Cit. 
 
1.3.3 Microvesicles 
In addition to NETs, activated neutrophils can also generate so called microvesicles (MVs), 
also known as microparticles.  
1.3.3.1 Definition 
MVs are commonly described as a heterogeneous population of small blebs with a diameter 
of 100 to 1000 nm [65]. These phospholipid vesicles are shed from the plasma membrane of 
not only neutrophils but from all cell types such as other leukocytes, platelets and endothelial 
cells during activation or cell death (apoptosis) [66], as illustrated in figure 3. 
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Figure 3. Release of microvesicles (MVs) from an activated or apoptotic cell. Reproduced 
with permission from Fariborz Mobarrez, PhD. 
Upon activation or apoptosis, small blebs called MVs are budded from the plasma membrane 
from cells such as leukocytes and platelets. The cell membrane of the MVs is rich in 
phosfatedylserine [65, 66], which make them negatively charged. MVs also carry antigens 
from the host cell, thereby enabling dissemination to other parts of the body.  
PS= Phosfatedylserine  
 
1.3.3.2 Function of microvesicles 
MVs can carry antigens and receptors from their cell of origin, thus transferring these 
surface-signaling molecules to other cells of different origin, initiating intracellular signaling 
pathways.  
Increased levels of MVs have been observed in various medical conditions, such as arterial 
thrombosis [66], diabetes [67], subarachnoid hemorrhage [68] and also in schizophrenia [69]. 
MVs are elevated in sepsis and may have deleterious effects on a number of tissues and may 
also contribute to organ dysfunction in septic shock [70, 71]. Furthermore, endothelial MVs 
have been proposed as a predictive biomarker of early septic shock-provoked disseminated 
intravascular coagulation (DIC) [72], even though the main part of circulating MVs in sepsis 
is platelet-derived [73]. Nevertheless, the use of MVs as a diagnostic and prognostic 
biomarker in sepsis remains elusive. MVs contribute to sepsis pathology in several ways, 
which is summarized in figure 4. 
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 Figure 4. Schematic of MV-actions in sepsis. Reprinted from "Microparticles: markers 
and mediators of sepsis-induced microvascular dysfunction, immunosuppression, and AKI." 
Souza, A. C., et al. (2015). Kidney Int. 87(6): 1100-1108, Copyright (2015), with permission 
from Elsevier.  
In response to microvascular injury associated to sepsis, immune cells such as platelets, 
endothel cells and neutrophils release mirovesicles (MVs). MVs can be both 
proinflammatory, immunosuppressive, as well as protrombothic that further enhance the 
microvascular injury.  
DIC = Disseminated intravascular coagulation; TNF-α = Tumor necrosis factor α, IL-10 = 
Interleukin 10. 
 
Additionally, MVs are elevated after endotoxin injection and can expose the pro-
inflammatory molecule HMGB1 and other cytokines [74]. MVs can also increase in blood 
during smoking, showing that MVs are sensitive for inflammation [75].  
  
Microvesicles 
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1.3.3.3 Methods of measuring microvesicles 
There are several methods of measuring MVs. Flow cytometry is the most commonly used 
method, thus enabling phenotyping of the MVs. To determine the origin of the MVs, samples 
are labeled with monoclonal antibodies against known cell-markers as illustrated in table 1 
below. 
 
Antigen  Parent cell  Alternative Name  
CD45 Leukocyte  
 
MPO/66b Neutrophils  
CD42a/41/61 Platelet  GPIX  
CD14 Monocyte  
CD62E  Endothelial cell  E-selectin  
Table 1. Antigens/cell-markers of different cell-types 
In this thesis CD42a (platelet marker), MPO and CD66b (neutrophil markers) have been used 
in order to phenotype MVs. 
 
1.4 LINK BETWEEN INFLAMMATION, COAGULATION AND MOF 
The fact that both NETs and MVs have been reported to be pro- coagulant [76, 77], illustrates 
the close link between inflammation and coagulation. Furthermore, platelets have been 
shown to have a prominent role in inflammation, triggering both the innate and adaptive 
immune system [78]. In a complex chain of events the imbalance between coagulation and 
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anti-coagulation, together with inflammation result in organ damage. Figure 5 illustrate the 
link between inflammation, coagulation and the resulting organ damage as a schematic. 
 
 
Figure 5. Link between inflammation, coagulation and organ dysfunction.  
Severe sepsis is associated with microvascular thrombosis and micro-vascular dysfunction. 
DAMP molecules e.g. LPS or external pathogens, trigger the immune system. Platelets 
activate and induce neutrophils to NETosis by presenting LPS through their TLR4 [40]. 
Circulating platelets are subsequently trapped in the NETs, which promote thrombus 
formation. NETs can also activate coagulation by the intrinsic pathway [79]. Activated 
immune cells, like neutrophils, platelets and endothelial cells, further release MVs that also 
have pro- coagulant activity [70]. Together with an impaired anti-coagulation, resulting from 
decreased levels of antithrombin, tissue factor pathway inhibitor and activated protein C, in 
addition to impaired fibrinolysis, due to an increased level of plasminogen activator inhibitor 
type 1 (PAI-1), thrombus formation increases. This results in tissue hypoperfusion, which is 
aggravated by vasodilatation, inducing low blood pressure. Together with an increased 
vascular leakage that produces tissue edema and a mitochondrial dysfunction, this tissue 
hypoperfusion result in organ dysfunction [6]. 
TLR4 = Toll-like receptor 4; LPS = Lipopolysaccharide; NETs = Neutrophil extracellular 
traps; MVs = Microvesicles; TF-inhibitor = Tissue Factor inhibitor; PAI-1 = Plasmin 
activator inhibitor type 1.  
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1.5 ENDOTOXIN STIMULATION AS EXPERIMENTAL INFLAMMATION 
Designing a clinical sepsis survey presents great challenge. This is due firstly, to that patients 
present at different stages of sepsis and secondly because of the diversity of microbiological 
patterns, as well as the heterogeneity among the patients. Therefore, experimental research is 
essential in order to increase the understanding of sepsis pathogenesis in a standardized 
manner. Numerous animal models using several species including rats, mice, rabbits, dogs, 
pigs and sheep have been described. Models include soft tissue infection, pneumonia model, 
meningitis model and intravascular infusion of live bacteria or endotoxin [80]. Endotoxin 
models is the focus within this thesis. 
1.5.1 Immune response following endotoxin stimulation 
Endotoxin/bacterial lipopolysaccharide (LPS) is incorporated in the cell membrane of most 
gram-negative bacteria, serving as a PAMP/signal flag, triggering the host-immune system 
and often induce the immunological septic reaction. The recognition of LPS by TLR4 on 
macrophages, induces the production of cytokines and other pro-inflammatory mediators 
through the Nuclear Factor Kappa-light-chain-enhancer of activated B-cells (NF κβ) 
pathway. This so called “stress-responsive” transcription factor, regulates the gene expression 
of different cytokines. The activation results in the synthesis and release of various cytokines 
considered characteristic for sepsis and the systemic inflammatory response syndrome 
(SIRS). NF κβ may also be induced by cytokines, through their respective receptors on the 
cell membrane [81]. 
Endotoxin is manufactured from the E. coli bacteria. It is used in the experimental setting to 
activate the immune system. Not containing the microorganism, it is a reliable, reproducible 
and widely used experimental method in both animals [82, 83] and humans [84-87].   
The inflammatory response, following endotoxin administration, depends on several factors, 
including dose and route of administration as well as host factors. Symptoms increase with a 
higher dose for all species and cytokine profile changes when a continuous infusion of LPS is 
used compared to when a single intravenous injection is administered as illustrated in figure 6 
[88]. Further, pigs have been reported more resistant to LPS compared to both primates and 
humans [89].  
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Figure 6. Plasma TNF-α after LPS (0.3 ng/kg), given either as an IV bolus injection or a 
4 hrs IV infusion in healthy volunteers.  Inspired by data and modified from Taudorf et al. 
Clin. Vaccine Immunol, 2007, 14(3), 250-255 [88] with permission by the Creative Commons 
Attribution 4.0 International license.  
TNF-α levels peaked earlier, at 2 hrs after LPS injection compared to the 4 hr IV infusion that 
peaked at 5 hrs post start.  
TNF-α = Tumor necrosis factor α; LPS = Lipopolysaccharide; IV = intravenous, ng/L = 
nanogram per liter  
 
1.5.2 Animal models 
In order to create an experimental septic shock-like state, higher doses of endotoxin have 
been utilized in pigs [83], mice [90] and baboons [91]. In order to obtain a sustained 
immunological reaction, endotoxin can be administered by infusion during the entire or part 
of the study time. In µg/kg doses of endotoxin, the LPS reaction is sudden and vivid in pigs, 
producing a decrease in systemic blood pressure and a transient increase in mean pulmonary 
pressure (MPAP) [83].  
1.5.3 Experience in humans  
Very low doses (< 1 ng/kg body weight) of endotoxin result in minimal changes in clinical 
signs, low levels of cytokines and short periods of depressed mood, reduced appetite, fatigue 
and cognitive impairment. Endotoxin doses of 2-4 ng/kg, elicits a series of symptoms and 
clinical signs that may show the initial phase of the immune activation [92].  
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1.5.3.1 Endotoxin (2-4 ng/kg) effects on immune cells and symptoms  
Clinical symptoms, like headache, usually occur 1 hr post LPS injection. Later increased 
body temperature, heart rate, myalgia, and nausea may appear. Recovery from these 
symptoms occurs after 8 to 12 hrs post LPS injection. Immediate release of cytokines [93, 
94] is followed by vasoconstriction [91]. Additionally, LPS activation induces a drop in 
white blood count (WBC) at 1hr, caused by neutrophil depletion during the first hour [87, 
93, 95]. The initial drop in circulating neutrophils has been explained as probable increased 
cell margination along the endothelium, due to both LPS and cytokine-mediated up-
regulation of vascular adhesion factors [87]. 
The leukopenia is followed by a leukocytosis, peaking at 8 hrs post LPS injection, before 
returning to baseline [84]. The leukocytosis may be explained by cytokines (e.g. IL 8) 
promoting the mobilization of neutrophils from bone marrow stores [87]. 
Further, Microvesicles derived from platelets (CD42a+), monocytes (CD14+) and endothelial 
cells (CD62E +) significantly increased after a bolus injection of LPS despite administration 
of hydrocortisone in human volunteers [74]. 
1.5.3.2 Endotoxin (2-4 ng/kg) effects on coagulation 
After endotoxin, an early activation of the fibrinolytic system occurs, which is then 
followed by a later and more prolonged activation of the coagulation [87]. Moreover, a 
moderate decline in platelets is a known effect of LPS stimulation [94]. The reason for this 
decline seems to be unknown. 
1.5.4 Difference between endotoxin stimulation and sepsis 
The endotoxin model has been criticized of being an artificial model not reflecting the clinical 
reality. Hence, since an actual bacteria is not involved, the reaction from LPS cannot be 
interpreted as sepsis. Moreover, different microbial agents can modulate the immune 
response differently [96]. Indeed, since LPS is just being one part of the gram-negative 
bacteria, it has been suggested that other parts of the cell membrane might be of importance 
in the sepsis reaction [80]. Further, in endotoxemia a more rapid increase in proinflammatory 
cytokines (e.g. IL-1β, IL-6 and TNF-α) has been reported, compared to the cytokine response 
in sepsis [97]. Therefore, in order to overcome these issues other animal models including 
cecal ligature and puncture (CLP) have been described [97].  
 
1.6 SOME TREATMENTS AIMING TO ATTENUATE MOF 
The most important measures in order to ameliorate the outcome in sepsis include early 
interventions like antibiotics and supporting vital functions, like normalized blood pressure 
by fluid resuscitation and inotropic drugs [17]. However, down below are presented some 
other treatments that have been used in sepsis therapy over the years and that will be 
considered within this thesis.  
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1.6.1 Inhaled Nitric Oxide 
Inhaled nitric oxide (iNO) attenuates pulmonary hypertension by selective relaxation of 
vascular smooth muscle cells in ventilated lung regions, thereby improving arterial 
oxygenation [98, 99]. Lately, it has been accepted that iNO also may have systemic effects 
[100, 101]. Neither the extent of iNO’s extra-pulmonary effects, nor the mechanisms, are 
entirely known. Though, it has been suggested that iNO is transported systemically by so 
called nitrosothiols. Nitrosothiols constitute of thiol groups attached to proteins and have 
been suggested to serve as nitric oxide (NO) donors outside the lung, through nitrite 
metabolites [102]. NO has also been shown to have anti-inflammatory effects, by inhibiting 
the expression of interleukins, adhesion molecules, cytokines and other inflammatory 
components like neutrophil infiltration [102-106]. 
In summary, these data suggest that iNO could possibly be a novel option in treating diseases 
characterized by systemic endothelial dysfunction.  
1.6.2 Glucocorticosteroid 
Glucocorticosteroid has well known anti-inflammatory effects, both by repressing the 
transcription factor AP-1, as well as inhibiting the transcription of the NF κβ- pathway [107]. 
In addition to the immunomodulatory effects, steroid administration may also have 
hemodynamic impact given in a low dose i.e. 200 to 300 mg/day of hydrocortisone or 
equivalent [107]. Some septic patients suffering from adrenal insufficiency, which makes 
them less sensitive to norepinephrine, have been reported to get an improved vasopressor 
response by hydrocortisone [108].  
Conflicting evidence have been reported about steroid use in septic shock. Two systematic 
reviews showed an improved septic shock reversal by use of a low-dose steroid treatment 
[109, 110]. However, while one of the aforementioned studies did find a decrease in mortality 
by prolonged low-dose treatment of steroid [109], the other did not [110]. A more recent 
study showed that patients with septic shock randomized to 200 mg of hydrocortisone/day for 
7 days had a quicker resolution of shock (3 vs. 4 days), a shorter duration of the initial 
mechanical ventilation (6 days vs. 7 days) and required less blood transfusion (37.0% vs. 
41.7%) compared to the placebo group [111]. Neither this study, nor a large European 
multicenter trial (CORTICUS) [112] could, however, prove any reduction in mortality in the 
hydrocortisone group.  
Still, the survival sepsis campaign [17] suggests a low dose glucocorticoid, intravenously 
(IV) of (< 200 mg/day) for patients with vasopressor resistant septic shock, in the absence of 
hypovolemia.  
1.6.3 Combination of iNO and glucocorticosteroid 
Hence, iNO and corticosteroid administration have both been shown to modulate the 
inflammatory process by among other actions, inhibition of NF-κB activation [105-107].  
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Da et al. [83] showed that iNO combined with intravenous (IV) hydrocortisone did have 
synergistic effects in organ protection. In a six-hour porcine endotoxemia model, 
administration of IV hydrocortisone simultaneously with iNO  
30 ppm almost preserved normal histology of the kidneys, liver and lungs, changed the 
pathophysiological reaction in a beneficial manner and blunted the inflammatory response. 
Renal, hepatic and pulmonary glucocorticoid receptors were down regulated by endotoxin 
infusion and subsequently up regulated by administration of iNO started after 3 hrs of 
endotoxin infusion.   
Conversely, Hållstrom et al. found no difference in cytokine expression between LPS only 
and LPS + iNO + IV steroid in a human endotoxin model (LPS 2 ng/kg) [86].  
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2 AIMS 
The overall aim of this thesis was to explore possible attenuating pathways in multi-organ 
failure after an endotoxin challenge in pigs and to better understand the immune response 
associated with endotoxemia. 
More specifically, the studies aimed to: 
• Report the effect on the multi-organ failure associated with prolonged endotoxemia 
(30 hrs) in pigs when treated with inhaled Nitric Oxide (iNO) 30 ppm, in 
combination with intravenous steroid (hydrocortisone, 75 mg x 3). (Paper I) 
 
• To methodologically validate a new enzyme-linked immunosorbent assay (ELISA) 
in order to quantify the levels of the potential sepsis marker citrullinated histone H3 
(H3Cit) in human plasma. (Paper II) 
 
• To assess the effect of endotoxin on circulating H3Cit, in a human model of 
endotoxemia and to investigate a possible presence and cellular origin of H3Cit-
bearing MVs. (Paper III) 
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3 ETHICAL CONSIDERATIONS 
3.1 PAPER I 
The experiments for paper I were conducted at the Institute of the Experimental Surgery and 
Biotechnology Research, Wroclaw University of Medicine. Ethical approval was obtained by 
the Animal Research Ethics Committee of the Institute of Immunology and Experimental 
Therapy, Polish Academy of Science, Wroclaw, Poland.  
When conducting animal experiments it is important to consider the tree R:s: Replacement, 
Refinement and Reduction. 
Replacement means that animal experiments cannot be replaced by any other methodology. 
This is the case when studying a new combination of drugs. Even if both iNO and steroid are 
already registered drugs for humans in Sweden, it is important to see if this new combination 
does improve outcome and that it does not have any adverse effects. Also, steroid is a 
controversial drug in the context of sepsis. Pigs and humans have a similar physiology and 
therefore, pig is a reasonable animal when testing new drugs, before proceeding to humans. 
Although it is regrettable that animals die, it might be for the sake of saving even more 
human lives in the long run. 
Refinement refers to that the animals should be well taken cared of before and during the 
procedure, so that they do not suffer. The subjects in study I were delivered from a farm and 
were hold during one night only at the veterinary hospital, where they were kept in a spacious 
facility and had free access to water. In order to avoid any possible suffering from the 
interventions during the study, animals were anesthetized. At endpoint, all animals were 
sacrificed in order to avoid any potential suffering caused by study interventions 
Reduction denotes the need to keep down the number of animals for an experiment, in order 
to prove a scientific outcome. In our study power was calculated in accordance to a previous 
study [83] indicating that 6 animals per group would be enough. Although, the spread of the 
data was vaster than anticipated in study I and we could not prove any significances in the 
end, despite previous power calculations.  
 
3.2 PAPER II-III 
The study rendering paper II-III, were conducted at the Department of Clinical Sciences, 
Danderyd Hospital and were approved by the regional ethical review board at Karolinska 
Institutet, in Stockholm, Sweden.  
It is however, reasonable to discuss the ethical considerations in administrating endotoxin to 
human volunteers. The short discomfort of the volunteers stands against that the endotoxemia 
model provides important information and insights regarding inflammatory conditions. Sepsis 
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is a major healthcare issue worldwide and could be hard to examine during the natural 
progression of the disease, as well as in cell lines or in animal models.  
In a safety perspective, human models of endotoxin inflammation have been used for several 
years worldwide and our research group alone has experience from over 200 volunteers 
exposed to LPS. Neither in the literature have any significant or permanent adverse effects to 
the administration of LPS in such experimental set-ups, been reported. Nevertheless, the 
volunteers have been reported to sometimes experience vagal reflexes that can be easily lifted 
by adequate medical care. Therefore, a specialist in anesthesia and intensive care surveyed 
the subjects, all through the study time. Also, as an extra safety measure, the study was 
conducted in close proximity to the intensive care unit at Danderyd hospital and all 
volunteers did a health exam before being included in the study. For female participants the 
health exam was completed with a pregnancy test on the trial day. 
Additionally, it is worth pointing out that all participants signed a written informed consent 
after a complete explanation of the study and no subject dropped out of this crossover trial. 
Moreover, in the end of the study, the volunteers answered the question anonymously if they 
would consider being included in a similar LPS study. All subjects said they would like to and 
for less of remuneration than they got for participating in this study. 
 
3.3 ETHICAL CONCLUSIONS FROM A PERSONAL POINT OF VIEW 
I think animal experiments are justified provided that 
1. There is an ethical approval justifying the experiment. 
2. The 3Rs are applied. 
3. The results contribute to save even more human lives. 
I find it acceptable to use endotoxin on human volunteers for the benefit of important 
knowledge, provided that the following criteria are met: 
1. Ethical approval assuring that the trial is conducted according to Good Clinical 
Practice (GCP), including e.g adequate information to the volunteers and informed 
concent. 
2. A health screening is conducted before inclusion, in order to assure healthy subjects. 
3. Adequate monitoring of the volunteers by authorized personnel. 
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4 SUBJECTS AND METHODS 
Table 2 summarizes the study designs from the papers included in this thesis. 
 
Paper Design Subjects Model Randomization (N) Outcome Time 
Hrs 
N
= 
I RCT Pigs Endotoxin 
(LPS) 
Control (6) 
LPS-only (6) 
LPS + iNO (6) 
LPS + IV steroid (6) 
LPS+iNO+IV steroid 
(6) 
Organ 
function 
30 30 
II Method 
validation 
Volunteers ELISA  
(LPS) 
LPS/Placebo H3Cit  22 
III Cross over Volunteers Endotoxin 
(LPS) 
LPS/Placebo H3Cit 7 22 
Table 2: Study designs within the thesis 
RCT = Randomized Controlled Trial, LPS = Lipopolysaccharide, iNO = inhaled Nitric 
Oxide, H3Cit = Citrullinated histone H3 
 
4.1 SUBJECTS 
4.1.1 Animals 
In paper I, 30 domestic piglets, two months old and with a median body weight of 21 kg 
(range 15-24 kg) were studied. The pigs were fasted over night prior to the study. 
4.1.2 Human volunteers 
For paper II-III, healthy volunteers were recruited through advertisements posted in 
university campuses. Before inclusion, all volunteers got a health examination. A flow chart 
of the inclusion process is presented in figure 7. 
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Figure 7. Flowchart illustrating the inclusion protocol for volunteers in paper II-III 
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Assessed for eligibility (n=39) 
Excluded  (n=17 ) 
♦			Not meeting inclusion criteria (n=11) 
♦			Declined to participate (n=3 ) 
♦			Other reasons (n= 3) 
Analysed  (n= 22) 
♦	Excluded from analysis  (n=0)	
Lost to follow-up (n=0 ) 
Discontinued intervention (give reasons) (n=0) 
Allocated to LPS first day (n= 11 ) 
♦	Received allocated intervention (n=11 )	
♦	Did not receive allocated intervention (give 
reasons) (n= 0 )	
Lost to follow-up (n= 0 ) 
Discontinued intervention (n= 0) 
Allocated to placebo first day (n= 11 ) 
♦	Received allocated intervention (n= 11)	
♦	Did not receive allocated intervention (give 
reasons) (n= 0 )	
Analysis	
Reverse	
intervention	
Day	B	
Randomized (n= 22) 
Enrollment	
Randomization	
Day	A	
(n=	0)	
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Twenty-two volunteers were included in the protocol. Demographics are shown in the table 3 
below: 
Variable Value 
Age, Mean (range) years 23.4 (19-34) 
Male No (%) 13  (59%) 
Weight mean (range) kg 70 ± (50-104) 
BMI, mean (range) kg/m2 22.9 ± 18-32 
Smokers No (%) 0 ± 0 
Drop outs No (%) 0 (0) 
Table 3. Demographics of healthy volunteers included in paper II and III 
 
4.2 ENDOTOXIN (LPS) ADMINISTRATION 
4.2.1 Paper I 
A septic shock-like condition was established by continuous intravenous infusion of 
endotoxin (Lipopolysaccharide (LPS) from E. coli (L2630-25MG, SIGMA, Gothenburg, 
Sweden, Chemical lot 110K4110, mixed in sterile water = 2 mg/ml). An initial dose of 5 
µg/kg/hr was administered for two hours after baseline measurements and then lowered to 
1µg/kg/hr, for the remaining 28 hours of the study period. An infusion allows for 
maintenance of the endotoxin shock during the 30 hr of study time. 
4.2.2 Paper II-III 
An intravenous injection of LPS 2 ng/kg endotoxin from E. Coli (Lot H0K354 CAT number 
1235503, United States Pharmacopeia, Rockville, MD, USA) was used, producing transient 
flue-like symptoms (headache, nausea, muscle pain, fever) lasting for about 7 hrs. The LPS 
powder was dissolved in 0.9 % physiological saline (NaCl) and treated for 10 min by 
ultrasound (Bransonic 3510, Bransonic Ultrasonic Corp, Danbury, USA) before 
administration in order to avoid flocculation. 
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4.3 RANDOMIZATION AND STUDY DESIGN 
The randomization for both studies was performed using sealed envelopes.  
For study I a randomized controlled study design (RCT) with parallel groups was used. The 
30 piglets were randomized into 5 groups and observed for 30 hrs as follows: 
1. Control: Anesthesia and mechanical ventilation without LPS infusion, iNO, or IV 
steroid. (N = 6) 
2. LPS-only: Continuous IV LPS infusion for the 30 hr study period. (N = 6) 
3. LPS + iNO: iNO at 30 ppm started after 3 hrs of IV LPS infusion and continued until 
the end of the experiment. (N = 6) 
4. LPS + IV steroid: IV hydrocortisone 75 mg started 3 hrs after IV LPS infusion and 
repeated every 8 hrs thereafter. (N = 6) 
5. LPS + iNO + IV steroid: Both continuous iNO at 30 ppm and IV hydrocortisone 75 
mg every 8 hrs starting after the initial 3 hrs of IV LPS infusion. (N = 6) 
A timeline illustrating study I, is presented in figure 8. 
For the human endotoxin study, rendering paper II-III, a double-blinded, randomized 
placebo-controlled, within-subject (cross over) design was used (fig 9). The 22 healthy 
human volunteers were randomly assigned to receive either a LPS injection or the same 
volume of 0.9 % NaCl on the first session of the study. Subjects were studied for 7 hrs. 
After 3-4 weeks of wash out period, the second session occurred in which subjects were 
assigned the reverse treatment. 
  
4.4 EXPERIMENTAL PROTOCOLS 
4.4.1 Specific protocol paper I 
The protocol was designed to evaluate the long-term effects of LPS on organ function, by 
various interventions.  
A flowchart describing the various experimental procedures is given in figure 8. Fluid and 
vasopressor supports were administered as needed (see below) to all groups.  
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Figure 8. Experimental protocol paper I. Reprinted from Göranson SP, Goździk W, Harbut 
P, Ryniak S, Zielinski S, Haegerstrand CG, et al. (2014) Organ Dysfunction among Piglets 
Treated with Inhaled Nitric Oxide and Intravenous Hydrocortisone during Prolonged 
Endotoxin Infusion. PLoS ONE 9(5): e96594. https://doi.org/10.1371/journal.pone.0096594. 
© 2014 Göranson et al. With permission under the terms of the Creative Commons 
Attribution License, open access. 
An LPS infusion of 5 µ/kg/hr was started at time 0 after instrumentation on anesthetized 
animals. Infusion was lowered to 1 µg/kg/h after 2 hrs and was kept on this level until the end 
of the study time at 30 hrs, when all animals were sacrificed. Treatment with either iNO, IV 
steroid (hydrocortisone) or a combination of both, was initiated 3 hrs post LPS infusion start. 
LPS = Lipopolysaccharide; iNO = inhaled nitric oxide: IV = intravenous; ppm = parts per 
million; µg = microgram; kg = kilogram 
 
4.4.1.1 Anesthesia and instrumentation 
Anesthesia induction was performed by an intramuscular injection of zolazepam/tiletamin 4 
mg/kg dissolved in medetomidine 0.08 mg/kg. Piglets were intubated and subsequently 
ventilated using a pressure-controlled mode on a Servo 900C ventilator (Siemens Elema-
Solna, Sweden). Ventilator was set at an inspired fraction of oxygen (FIO2) of 0.3, a PEEP of 
5 cm H2O and the inspiratory pressure aimed to keep the piglets normo-ventilated.  
For maintenance of the anesthesia an IV infusion of a mixture of ketamine 1.5-2.4 mg/kg/hr, 
medetomidine (5.3-8.2 µg/kg/hr), fentanyl (0.8-1.3 µg/kg/hr), and midazolam (0.08-0.13 
µg/kg/hr) was used. During instrumentation, anesthetic doses were increased in order to avoid 
stress. Anesthesia doses were then lowered to standard sedation doses, for the rest of the 
study time. Instrumentation included insertion of a femoral arterial line (BD Careflow 
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femoral artery catheter®, Becton Dickinson, Singapore, Singapore) and a supra-pubic urinary 
bladder catheterization by a mini laparotomy (Rüsch catheter, Kernen, Germany). By internal 
jugular cut down both a balloon tipped flotation catheter with a thermistor (PAC) (CritiCath 
SP5105H TD catheter®, Becton Dickinson, Singapore, Singapore) as well as a central venous 
catheter (CVC) (BD Careflow central venous catheter®, Becton Dickinson, Singapore, 
Singapore) were inserted. The tip of the PAC was advanced into the pulmonary artery. In 
order to evacuate any ascites fluid, a drainage tube was finally inserted into the abdominal 
cavity. Baseline data (=time zero) were registered after a 1hr recovery period and the blood 
was sampled from the arterial catheter.  
4.4.1.2 Administration of iNO and IV steroid 
Inhaled nitric oxide (iNO) (Pulmonox-Messer Griesheim 800 ppm NO in 9000 nitrogen) was 
delivered at 30 ppm by a Pulmomix Mini (Messer Griesheim, Gumpoldskirchen, Austria) to 
the inspiratory limb of the ventilator as described previously [101]. 
4.4.2 Specific protocol paper II-III 
The protocol was designed to assess the effect of LPS on circulating H3Cit. 
 
Figure 9. Experimental protocol and study design paper II-III 
After randomization subjects received either an LPS or a saline injection intravenously. 
Plasma analyzed was sampled at baseline (T0) and 2, 4 and 7 hrs post LPS injection. After 3-
4 weeks of washout, volunteers were subjected to the inverse intervention. 
LPS= Lipopolysaccharide (2 ng/kg), Placebo = Saline (NaCl) 0,9%, T= Time in hrs after 
injection, Sampling= Blood sampling for microvesicles, citrullinated histone H3, white blood 
cell count and cells, cytokines and full blood count. 
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After arrival the subjects had two intravenous catheters. One was used for the LPS/saline 
injection (22G) and was removed immediately after the injection. The other was placed in the 
opposite antecubital fossae (17G) and was used for blood sampling. All volunteers and 
research staff were blinded, except the physician involved in the study for security purposes. 
 
4.5 MONITORING  
4.5.1 Monitoring paper I 
Continuous monitoring included pulse oximetry (SpO2), a three-point electrocardiogram 
(ECG), recordings of heart rate (HR), end-tidal carbon dioxide concentration (EtCO2) 
(General Electric health care AS/3 Instrumentarium, OY Helsinki, Finland), fraction of 
inspired oxygen (FIO2). pulmonary arterial-, central venous- and mean systemic pressures, 
(MPAP, CVP and MAP). Thermo-dilution cardiac output (CO, L/min) and pulmonary 
capillary wedge pressure (PCWP, mmHg) were measured every 4 hrs. Pulmonary- (PVRI) 
and systemic (SVRI) vascular resistance indexes (dynes-sec /cm-5/m2) were calculated out of 
the measurements obtained from the PAC and artery line. Urinary output was registrated and 
the urinary reservoir emptied after 12, 24, and 30 hrs of endotoxin infusion. The PAC 
thermistor recorded central body temperature, in order to keep the animals normothermic (37-
38°C). Hypothermia was avoided by use of heating blankets, or external cooling when 
necessary. Every 4 hrs, the animals were turned side to side.  
MAP less than 60 mmHg for longer than 3 min was defined as hypotension in need of 
treatment.  Hypotension treatment started with a lactated Ringers solution bolus, or a rapid 
infusion of hydroxyl ethyl starch (HES). HES was given at a maximum dose of 750 ml. 
Norepinephrine infusion (40 µg/ml) was initiated if fluid bolus was inefficient in restoring 
MAP to > 60 mmHg. Central venous pressure (CVP) aimed to be between 6 and 8 mmHg.  
In order to maintain the blood glucose and to compensate for fluid loss, a mixture of 2.5% 
glucose in saline 0.9% (Glucose/NaCl 1:1, Braun, Melsungen, Germany) at a basal infusion 
rate of 100 ml/hr, was administered during the study time. Low or high blood glucose levels 
were not treated. In order to counteract bradycardia, Glycopyrrolate 0.2 mg was mixed into 
the infusate of 1500 mL. Additionally, cefuroxime (GlaxoSmithKline, Solna, Sweden) was 
administered at a dose of 500 mg IV every 8 hrs, in order to avoid septicemia due to 
accidental bacterial contamination from instrumentation.  
4.5.2 Monitoring paper II-III 
Visual Analog Scale (VAS) was used for assessment of nausea, headache and lower back 
pain every 30 min throughout the experiment. Tympanic temperature (ThermoScan pro 1, 
Thermoscan Inc. San Diego, USA), respiratory rate, peripheral oxygen saturation (SpO2), 
pulse, ECG monitoring, non- invasive blood pressure (Philips Intellivue X2, Boeblingen 
Germany) were registered.  
  29 
4.6 SAMPLING 
4.6.1 Specific blood sampling paper I 
After instrumentation and a subsequent recovery for one hour, blood samples were drawn, 
from the artery line, at baseline, 0 hr (immediately prior to starting LPS infusion and then at 
6, 12, 24, and 30 hrs after baseline. Samples included white blood cell cell (WBC) count, 
interleukin 1 and 10 (IL-1, IL-10), tumor necrosis factor α (TNF-α), alanine aminotransferase 
(ALAT), creatinine, urea, sodium (Na), potassium (K), chloride (Cl), and platelet count. 
Point-of-care analysis of blood gases (ISTAT, Abbot, East Windsor, USA) included pH, 
PaCO2, PaO2, bicarbonate (HCO3 -), lactate, and base excess (BE). High or low potassium 
levels and acidosis were not treated. Blood drawn for interleukins was immediately 
centrifuged (Hettich Zentrifugen Universal 16R, Hettich Gmb&H, Tuttlingen, Germany) for 
ten min at 4000 g/min. The supernatants were stored at -70ºC until analyzed. The remaining 
parameters (WBC, ALAT, creatinine, urea, Na, K, Cl, and platelets) were analyzed within 
one hr.  
4.6.2 Specific blood sampling paper II-III 
Blood samples were taken through an intravenous cannula at baseline (0 hr) and then at 1 hr, 
1.5, 2, 3, 4, 5 and 7 hrs post baseline. If blood could not be drawn easily from the cannula, 
direct blood sampling was performed. However, papers presented in this thesis only include 
analyzed blood samples from 0, 2, 4 and 7 hrs post LPS injection.  
4.6.2.1 Microvesicles and citrullinated histone H3 
Samples from sodium citrate tubes were centrifuged immediately at 2000g for 20 min at 
room temperature and the samples were stored as platelet-poor plasma at -80°C until analysis 
for MVs and H3Cit. 
4.6.2.2 Cytokines, blood count and cells 
Blood samples from EDTA tubes were centrifuged and plasma was aliquoted and stored at -
80°C until the analyses. Plasma levels of the inflammatory cytokines, IL-6, TNF-α and IL-8, 
were measured using multiplex assays (Human Mag Luminex Performance Assay, 
LHSCM000, LHSCN206, LHSCM208, LHSCM210, RnD Systems, MN, USA). 
 
4.7 SPECIFIC METHODS 
4.7.1 ELISA (paper II-III) 
Due to the lack of objective and quantitative methods to assess levels of citrullinated histone 
H3 (H3Cit) as a marker for systemic NET burden, a novel ELISA-based assay (paper II) was 
methodologically validated.  
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In lack of samples of known concentrations, we chose to use plasma samples obtained from 
the human endotoxin study described above, assuming that inflammation would induce a 
systemic NET formation resulting in elevated levels of H3Cit in plasma. This hypothesis was 
based on previous results by others, demonstrating detectable H3Cit levels by western blot in 
a mouse model, 3 hrs post LPS injection [64]. Consequently, in line with these data, human 
plasma samples 3-4 hr post IV injection of LPS (2 ng/kg of body weight) assumed to be 
suitable for the H3Cit assay validation.  
An anti-histone antibody served as a capture antibody for the assay. For detection an anti-
histone H3 citrulline antibody was used (fig 10). A standard curve was obtained, using in 
vitro PAD4-citrullinated H3Cit [113]. Incubation times, dilutions of samples and the 
concentrations of the standard curve were optimized in preliminary experiments. 
 
 
Figure 10. Schematic of the H3Cit ELISA. Reprinted from Thålin, C., Daleskog, M., 
Göransson, S.P. et al. Immunol Res (2017) 65: 706. https://doi-
org.proxy.kib.ki.se/10.1007/s12026-017-8905-3. © Thålin et al 2017, with permission under 
the terms of the Creative Commons Attribution License, open access.  
A – To a streptavidin coated well, the anti-histone Biotin (capture antibody) is added and 
incubated. Plasma samples are pipetted into the wells. Histones present in the sample bind to 
the capture antibody during a second incubation. B - After washing, an anti-H3Cit antibody is 
added to the wells. In a third incubation, Anti-H3Cit binds to citrullinated histone H3 (H3Cit) 
but not to non-citrullinated histone H3. C - A horseradish peroxidase (HRP) conjugated anti-
rabbit antibody is added in a fourth incubation. This antibody binds to the Anti-H3Cit. 
Finally, Tetramethylbenzidine (TMB) is added for detection. 
H3Cit = Citrullinated histone H3; HRP = Horse Radish Peroxidase; TMB = 
Tetramethylbenzidine 
Figure'1'
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The assay was evaluated in accordance with recommended ELISA validation requirements 
[114] for the following: 
1. stability,  
1. linearity   
2. limit of detection, 
3. specificity,  
4. recovery/effect of the matrix, 
5. precision and reproducibility.  
Trueness could not be determined as there is no available assay or reference analyte of known 
concentration for comparison. 
Stability was assessed by comparing the standard curves for three different batches of frozen 
H3Cit standard, prepared on three different days. A freshly prepared H3Cit standard was also 
compared with a frozen aliquot. 
The suitable linear interval, i.e. the measuring interval, was defined as the linear section of 
the best-fit standard curve. It was determined by interpolating the detected optical density 
(O.D.) from serial dilutions of H3Cit to different regressions. The 95% confidence interval 
(95% CI) was considered.  
The limit of detection was first approximated by assessing the minimum level at which 
H3Cit could be detected in serial dilutions of positive samples. Each standard curve was fitted 
using a four-parameter logistic (4PL) regression to the calibration curve and the 95% CI was 
considered. The limit of detection was finally set by comparing the approximated level to the 
concentration corresponding to the highest O.D. at the bottom 95% CI. 
Specificity was assessed by the ability to detect citrullinated histone H3 in the presence of 
non-citrullinated histone H3. A standard without PAD4 was prepared, thus preventing the 
citrullination of histone H3.  
Recovery and the effect of the matrix were assessed by spiking plasma samples from four 
healthy volunteers with known concentrations (625, 312, 156, 78, 38, 19 and 10 ng/ml) of in 
vitro PAD4-citrullinated H3Cit.  
To further assess the effect of the matrix, the standard was prepared in healthy plasma diluted 
in Phosphate-Buffered Saline (PBS); dilutions 1:20, 1:10 and 1:5. 
Precision/Reproducibility was assessed by measuring six replicates of eight samples within 
the same assay (intra assay) and by comparing the same eight samples (in duplicates) in four 
different assays runs, on four different days (inter assay). Reproducibility was considered 
acceptable if the coefficient of variation (% CV), defined as the ratio between standard 
deviation and mean value) was less than 15%. 
4.7.1.1 Detection of plasma H3cit by ELISA (Paper III) 
Plasma samples were thawed on ice. H3Cit was quantified by the capture ELISA described 
and validated  in paper II and explained  in detail above. Briefly, H3Cit levels were obtained 
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by use of an anti-histone antibody as capture antibody (Roche, Basel, Switzerland), and 
subsequently an anti-histone H3 citrulline antibody for detection (Abcam, Cambridge, UK). 
To measure the portion of MV-bound H3Cit in the samples, the same ELISA assay analysed 
H3Cit in an MV-free supernatant and an MV-enriched pellet after high-speed centrifugation 
of the plasma. 
4.7.2 Flow cytometry (paper III) 
Flow cytometry is the golden standard for measuring MVs, due to its ability of measuring 
multiple protein expression. This ability allows for phenotyping (speciate) the MV. 
A schematic figure of the flow cytometer is shown in figure 11 
 
 
Figure 11. Basic principals of flow cytometry. Reproduced with permission from Fariborz 
Mobarrez, PhD.  
The MVs pass through a flow chamber filled with PBS. A laser beam spots the MVs as the 
flow chamber narrows down, producing both a forward scatter (FSC),”measuring size”, and a 
side scatter. The nature of the scattered laser depends of the size and complexity of the 
particle.  
If an MV is conjugated with a fluorescent antibody, it can be detected by the flow cytometer 
by its fluorescent signal emissions, creating different colors of the light beams. This allows 
for the MV to be phenotyped. Several cell properties can further be measured simultaneously 
by labeling MVs with multiple antibodies, each with a different fluorochrome or “color”. 
[115]. Examples of antibodies used within this thesis are CD66b and myeloperoxidase 
  33 
(MPO) for neutrophil detection and CD42a for platelet detection, as well as anti-H3Cit 
antibody for detection of H3Cit-bearing MVs. Fluorochromes used were allophycocyanin 
(APC), phycoerythrin (PE) and fluorescein isothiocyanate (FITC).  
The light emissions are detected and digitized for analysis by a computer and are usually 
displayed in dot-plots or histograms. 
4.7.2.1 Detection of plasma MVs by flow cytometry 
Plasma samples were centrifuged at 2000 g for 20 min at room temperature (RT), after being 
thawed once in water bath, 37° C. Re-centrifugation of the supernatant was performed at 
13000 g for 2 min at RT. Thereafter, 20 µl of the supernatant was incubated for 20 min in 
dark, with 5 µl of anti-histone H3 citrulline antibody (Abcam, Cambridge, UK) in order to 
detect H3Cit-bearing MVs, CD66b APC (Beckman coulter, Brea, CA, USA) and MPO PE 
for the detection of neutrophil-derived MVs, as well as CD42a FITC (Beckman coulter, Brea, 
CA, USA) for the detection of platelet-derived MVs (Beckman coulter, Brea, CA, USA). 
Levels of MVs were detected by flow cytometry on a Beckman Gallios instrument (Beckman 
coulter, Brea, CA, USA). The use of Megamix-Plus FSC beads (0.3, 0.5 and 0.9 µm in size; 
BioCytex, Marseille, France) was used in order to determine the MV gate. MVs were defined 
as particles less than 0.9 µm in diameter (forward scatter). As negative controls, conjugate 
isotype matched immunoglobulins, with no reactivity against human antigens were applied. 
In this thesis, results are shown as numbers of MVs (MV counted x standard beads 
added/L)/standard beads counted (FlowCount, Beckman Coulter, CA, USA). The inter- and 
intraassay coefficients of variation for MV measurement were less than 9% respectively. 
4.7.2.2 Incubation of purified H3Cit with in vitro generated platelet-derived MVs 
The binding properties of H3Cit to MVs were examined by experiments in vitro. From fresh 
platelets extracted from healthy donor blood, a high concentration of platelet-derived MVs 
was generated by centrifugation. In short, in order to obtain a platelet-rich plasma (PRP), 
citrated whole blood was centrifuged at 200 g for 10 min at RT. The platelet agonist ADP (35 
µM, Roche, Basel, Switzerland) was then used to activate the PRP, during 20 min at RT, 
rendering platelet-derived MVs. When activated, the PRP was centrifuged at 2000 g for 20 
min at RT in order to separate platelets from the supernatant with platelet-derived MVs. The 
supernatant was then re-centrifuged at 20 800 g for 45 min at RT twice (phosphate-buffered 
saline wash in between). By removing the supernatant, an MV-enriched pellet was created 
and was aliquoted into three samples (N = 3). The MV-enriched samples were labeled with 
lactadherin and anti-histone H3 citrulline, thereby determining baseline levels of PS exposure 
and H3Cit. Briefly, each sample measuring 20 µl, was labeled with 5 µl of lactadherin FITC 
(Haematologic Technologies, VT, USA) and anti-histone H3 citrulline Dylight 755. The 
samples were then measured by flow cytometry (described above), after 20 min incubation in 
RT. The MV-enriched samples were subsequently incubated with increasing concentrations 
of H3Cit peptide (abcam, Cambridge, UK), 0 – 1500 ng/ml, for 90 min at 37 °C. The samples 
were once again labeled with lactadherin FITC as well as with anti-histone H3 citrulline 
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Dylight 755 and measured by flow cytometry. MVs were phenotyped based on their PS 
exposure and expression of H3Cit and were defined as particles less than 0.9 µm in size 
(forward scatter). 
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5 STATISTICAL ANALYSES 
Appropriate statistical method was chosen according to the nature of the data and was 
adjusted to fit the study design. Normally distributed data was presented as mean and 
standard deviation (SD). Skewed data were presented as median and range/interquartile range 
(IQR). A p-value of < 0.05 was considered significant. 
 
5.1 SPECIFIC STATISTICS PAPER I 
The main research question in paper I was to identify differences between the different 
treatment groups (N = 3) vs LPS-only in a randomized control study design (independent 
data).  
Due to the low sample size, in combination with mostly skewed data, non-parametric tests 
were used. To evaluate the treatment effect over time, a Wilcoxon signed rank test was used 
to compare the difference between end-point (30 hrs) vs baseline for each group. A 
Wilcoxon-Mann-Whitney test was then performed in order to compare the difference in 
treatment effect between groups at endpoint. Due to multiple group comparisons (LPS vs 1. 
LPS + iNO; 2. LPS + steroid and 3. LPS + iNO + IV steroid) a Bonferroni Holm correction 
was subsequently performed.  
Further, a Kruskal Wallis was performed for all base line data, in order to assure a non-
significant difference between the groups before randomization.  
For subjects that died, but lived until at least 20 hrs post start of LPS infusion, last-
observation-carried-forward method, based on the intention-to-treat principle was applied. 
This was the case for 2 out of 3 deaths. 
 
5.2 SPECIFIC STATISTICS PAPER II 
The aim of paper II was to validate an H3Cit ELISA.  
The nominal log concentration was fitted versus O.D., applying a sigmoidal 4PL regression 
to the calibration curve in order to specify linearity. 4PL curves were then compared by F-
test.  
In order to demonstrate precision and reproducibility, the variation of inter- and intra-assay 
experiments were presented as coefficient of variation (CV). CV was defined as the ratio of 
the SD to the mean (%). 
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5.3 SPECIFIC STATISTICS PAPER III 
The aim of paper III was primarily to study dynamics of the biomarker H3Cit over time in a 
cross over design (dependent data). 
In order to adjust for multiple time points a repeated measures ANOVA was used if the data 
was normally distributed. If data were skewed, despite log transformation, a generalized 
mixed model (GEE) was used. The ANOVA or GEE was based on the differences between 
LPS- placebo for each time point (dependent data). The covariate ”trial day” (the day the 
subject got LPS) was applied in order to prove sufficient wash out from LPS. Further, the 
covariate ”time” (change over time) was included in the repeated measures model. 
Post hoc comparison was allowed for if the repeated measures model was significant. A 
Wilcoxon signed rank test was used both for normally and not normally distributed data, due 
to the relatively low number of subjects in the study (N = 22) in line with the central limit 
theorem. Since the dynamics over time were the main focus of interest, statistics were 
analyzed mainly for the change over time between the LPS versus the placebo arm. 
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6 RESULTS 
This section will summarize the results in brief and as an overview. Detailed information is 
presented in the separate papers. Results presented in this part will focus on organ function 
and H3Cit/MV response. 
 
6.1 COMPARISON OF REACTIONS TO ENDOTOXIN ADMINISTERED AS 
INFUSION OR INJECTION  
6.1.1 General physiological symptoms from endotoxin 
When IV LPS was given in a µg dose and as an infusion to piglets (paper I) more 
pronounced and sustained physiological changes were apparent compared to the 
administration of a single injection IV in a ng-dose to humans (paper II-III). Exposure to the 
LPS infusion caused a decrease in MAP, increased peak inspiratory pressure, impaired gas 
exchange and elevated serum creatinine in pigs. Meanwhile, healthy human volunteers 
injected with a single ng-dose of LPS IV, experienced headache, nausea, chills and fever. The 
symptoms started promptly at 1 hr post LPS injection and were most intense during the 
subsequent hr. After 7 hrs symptoms had more or less abated. No significant difference in 
hemodynamics was seen between the LPS and the placebo arm, except for heart rate 
increasing significantly with temperature at 3 hrs. 
6.1.2 White blood cell count and platelets 
In accordance with previous data [94] a drop in white blood cell (WBC) count were seen in 
humans after LPS IV injection, in which the decrease corresponded to a drop in neutrophil 
count (fig 12D). Also pigs with a continuous IV infusion of LPS exhibited a drop in WBC 
count, but later, after 6 hrs of LPS infusion (12A), as shown in figure 12. Interestingly groups 
treated with iNO (LPS + iNO and LPS + iNO + IV steroid) did not exhibit this drop.  
Platelets decreased significantly over time (p < 0.001) in LPS treated groups in both LPS 
injected humans (fig 12E) and pigs exposed to LPS infusion. Interestingly, also the healthy 
control animals experienced a drop in platelets (fig 12B). Leukocytosis was more pronounced 
in pigs after the higher dose of LPS as infusion (fig 12A) than after the IV injection of 2ng/kg 
given to humans (fig 12C).  
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Figure 12. White blood cell count and platelets in LPS infusion (pigs) (A-B) compared to 
LPS injection (humans) (C-E). 
There was a drop in white blood cell count with a subsequent leukocytosis after endotoxin 
infusion (A) as well as after injection (C). This drop corresponded to a drop in neutrophils as 
illustrated for the human data (D). Platelet levels decreased significantly over time (p <0.001) 
for LPS infusion (B) and LPS injection (E). 
WBC = White blood cell count; LPS=Lipopolysaccharide; iNO = inhaled nitric oxide; IV = 
intravenous; Control = sham animals or humans exposed to saline injection, no LPS given; 
time = change in plasma-levels of WBC/neutrophils/platelets over the study time; Data are 
presented as median and intraquartile range (IQR); N = 22 for humans and 30 (6 /group) for 
animals. 
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6.1.3 Cytokine response 
Further, cytokines were significantly elevated after endotoxin in LPS treated individuals. No 
significant dynamics were seen for any cytokine measured in the studies. All cytokines (TNF-
α, IL-1β, IL-10 in paper I and TNF-α, IL-6 and IL-8 in paper II-III) were significantly 
elevated over time after endotoxin administration.  
During continuous infusion in pigs IL-10 and TNF-α levels peaked at 6 hrs whereas IL-1β did 
not peak until 12 hrs. At the 30 hr endpoint, all cytokines approached baseline. 
In humans TNF-α was the first cytokine to peak at 1.5 hrs after LPS injection of 2 ng/kg, 
corresponding to highest VAS score for headache followed by a subsequent simultaneous 
peak of IL-6 and IL-8 at 2-3 hrs post LPS injection that matched fever. All cytokines had 
returned to baseline at the 7 hr endpoint.  
Differences in TNF-α levels when comparing infusion in pigs and injection in humans, are 
illustrated in figure 13 and were in accordance with previous reported data [87]. TNF-α 
profile changed during infusion of LPS compared to after LPS injection. During infusion 
TNF-α peaked later (at 6 hrs) compared to when administered as an injection when the peak 
was at 1.5 hrs. Higher dose of LPS generated a more pronounced response in TNF-α. 
 
Figure 13. TNF-α levels in pigs during LPS infusion (5 µg/kg lowered to 1µg/kg) (A) 
compared to after LPS injection (2ng/kg) in humans (B) 
A) During continuous LPS infusion in pigs, TNF-α peaked at 6 hrs and did not quite reach 
baseline in the end of the 30 hrs study time. There was a trend towards lower TNF-α levels in 
the treatment groups compared to LPS alone, but no significant difference was seen. B) TNF-
α levels peaked earlier at 1.5 hrs after LPS injection of 2 ng/kg in humans than during 
infusion. Baseline levels of TNF-α were noted 7 hrs post LPS injection in humans. TNF-α = 
Tumor necrosis factor α; LPS = Lipopolysaccharide; iNO = inhaled nitric oxide; IV = 
intravenous; Control = sham animals or humans exposed to saline injection, no LPS given; 
pg/mL= pikogram/milliliter; time = change in TNF-α-levels over the study time; Data are 
presented as median and IQR. N = 22 for humans and 30 (6/group) for animals.  
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6.2 EFFECTS OF INO + IV STEROID IN A PORCINE ENDOTOXEMIA MODEL 
(PAPER I) 
6.2.1 Mortality and causes 
There was no death in the Control group or in the LPS + iNO + IV steroid group. Other LPS 
exposed groups had 1 case of death each. Details are presented in table 4.  
 
 Control LPS-only LPS + 
IV steroid 
LPS +  
iNO 
LPS +  
iNO+IV steroid 
Deaths N 0 1 1 1 0 
Timepoint of 
death 
 6 hrs 20 hrs 18 hrs  
Cause of 
death 
 High MPAP 
with respiratory 
failure 
Severe 
shock 
Circulatory 
failure 
 
Table 4.  Mortality details paper I 
LPS = Lipopolysaccharide; iNO = inhaled nitric oxide; IV = intravenous; MPAP = mean 
pulmonary artery pressure; ; Control = sham animals, no LPS given; N = number of deaths 
out of 6 animals per group; hrs = hours 
 
6.2.2 Renal function 
Renal function after LPS infusion is summarized in figure 14 below: 
 
 
Figure 14. Renal failure after endotoxin infusion in pigs tended to be less in the LPS + 
iNO + IV steroid group when compared to LPS-only.  
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A) Creatinine tended to be lower in LPS + iNO + IV steroid treated pigs compared to LPS, 
but there was a big spread in the data. A significant different could be seen between LPS 
alone and control (p < 0.05). No significances were seen between other groups compared to 
LPS alone. However, B) Base excess was significantly higher/better in LPS + iNO + IV 
steroid treated pigs compared to LPS-only.  
LPS = Lipopolysaccharide; iNO = inhaled nitric oxide IV = intravenous. Control = sham 
animals, no LPS given; Data are presented as median and range. N = 30 (6/group) * p < 0.05 
= Comparison of distribution of differences versus LPS-only (Bonferroni-Holm adjusted p-
value); Data are presented as median and intraquartile range; N = 30 (6/group). 
6.2.3 Hemodynamics 
In order to obtain a MAP of a minimum of 60 mmHg, initially fluids were infused to a CVP 
up to 6-8 mmHg. If MAP was still less than 60 mmHg, norepinephrine was titrated. There 
was no significant difference between groups in the amount of fluids administered. However, 
the total amount of norepinephrine given tended to be lower in the LPS + iNO + IV steroid 
group compared to the LPS-only group (p < 0.05; Bonferroni-Holm corrected p = 0.1) 
(fig.15). Further, the LPS + NO + IV steroid group only required norepinephrine during the 
initial 4 hrs of the study time (1 hr post treatment start). LPS + IV steroid showed a similar 
pattern, but 2 pigs required norepinephrine even after 4 hrs.  
 
Figure 15. Total amount of norepinephrine administered over the study time in study I. 
Norepinephrine consumption tended to be less in steroid treated groups (LPS + IV steroid and 
LPS + iNO + IV steroid) compared to LPS-only. Healthy control pigs were given 
significantly less norepinephrine (p < 0.05) compared to LPS-only.   
LPS = lipopolysaccharide; iNO = inhaled nitric oxide; IV = intravenous; Control = sham 
animals, no LPS given; * p < 0.05 compared to LPS-only; Data are presented as median and 
IQR; N = 30 (6/group). 
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6.2.4 Pulmonary function 
We could not see a significant difference in iNO treated groups (LPS + iNO and LPS + iNO 
+ IV steroid) neither in mean pulmonary pressure (MPAP) (fig. 16A) nor in PaO2/FiO2 (fig. 
16 B) compared to LPS-alone. However, there was a trend towards that iNO lowered the 
MPAP and increased the PaO2/FiO2.  
  
Figure 16. Treatment effect on pulmonary function 
There was a trend towards a decreased MPAP and an increased PaO2/FiO2 in iNO-treated 
groups (LPS + iNO and LPS + iNO + IV Steroid) compared to LPS + IV Steroid and LPS-
only. 
LPS = Lipopolysaccharide; iNO = inhaled nitric oxide; IV = intravenous; Control = sham 
animals, no LPS given; kPa = kilo Pascal; mmHg = millimeter of mercury; time = change in 
in MPAP or PaO2/FiO2 over the study time; Data are presented as median and IQR; N = 30 
(6/group). 
 
 
6.3 VALIDATION OF A H3CIT ELISA (PAPER II) 
An H3Cit ELISA in order to quantify levels of plasma H3Cit was methodologically 
validated. 
The best-fit curve turned out to be a sigmoidal 4PL curve providing a linear interval of the 
curve with a range of ≈ 0.5 and 3.5 O.D., matching concentrations rangeing between ≈ 5 and 
≈ 300 ng/mL. 
In order to determine the limit of detection, the lowest detectable concentration was defined 
by approximation of the lowest detectable concentration obtained by the curve to ≈ 5 ng/mL, 
consistent with the 4PL match of the standard curve and the intersection of the lower 
asymptote of the upper 95% CI. The stated probability of the limit of detection was therefore 
set to approximately 5 ng/mL. 
Three different batches of frozen H3Cit-standard, prepared on three different days and with 
different batches of PAD4 were compared for detector response, without significant 
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differences (fig. 17A). Similarly, no significant difference could be identified in the detection 
response obtained from a standard prepared from freshly citrullinated H3Cit contrasted to a 
standard prepared from frozen aliquots of H3Cit (fig. 17B), exposing a high stability and 
further allowing for high reproducibility. 
The detection response of non-citrullinated histone H3 was considered negligible within the 
linear interval of the assay, despite a low detection response when identifying large quantities 
of non-citrullinated histone H3, verifying a high specificity for citrullinated H3 (H3Cit) 
within the linear interval of the assay (fig. 17C)  
Recovery could not be obtained by adding/“spiking” known concentrations of H3Cit into 
plasma from healthy individuals (fig. 17D), probably indicating an “effect of the matrix” (in 
this case; plasma). 
 
Figure 17. Stability and specificity. Reprinted from Thålin, C., Daleskog, M., Göransson, 
S.P. et al. Immunol Res (2017) 65: 706. https://doi-org.proxy.kib.ki.se/10.1007/s12026-017-
8905-3. © Thålin et al 2017, with permission under the terms of the Creative Commons 
Attribution License, open access. 
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A) Illustrating similar detector responses of three standard curves prepared from three 
different batches of deep-frozen PAD4-citrullinated histone H3, or B) from frozen aliquots of 
H3Cit or freshly citrullinated H3Cit (F (DFn, DFd)= 2.6 (8,9); p= 0.088, and F (DFn, DFd)= 
0.2 (4, 52); p= 0.916 respectively). C) Results acquired when preparing a standard curve with 
histone H3 that was incubated during the same circumstances as the standard preparation of 
H3Cit, but in lack of PAD4, resulting in non-citrullinated histones, illustrative of three 
different experiments. A low amount of antibody antigen was detected when large quantities 
of non-citrullinated histone H3 was added, but the antibody antigen detection was shown to 
be specific for H3Cit within the linear interval of the assay. D) No detectable H3Cit could be 
measured in plasma from healthy individuals. However, spiking of known concentrations of 
H3Cit into plasma diluted in proportions 1:2 yielded a significantly lower detector response 
when comparing with the detector response achieved from the standard prepared from PBS-
1% BSA, implying an effect of the matrix.  
H3Cit = Citrullinated Histone H3; PAD4 = Protein arginine deiminase 4; H3 = Histone 3; 
STD = Standard solution with known concentrations of H3Cit; PBS = Phosphate buffered 
saline. 
 
In all samples taken at baseline, the levels of H3Cit were under the detection limit of 5 
ng/mL. Further, in all samples taken from the very same individuals 3-4 h after LPS injection, 
H3Cit levels ranged between 28.7 ng/mL and 93.2 ng/mL. The CV were all <15 %, with an 
intra-assay variation ranging between 2.13-5.15 %. The inter-assay variation ranged from 
5.80-12.55 %, indicating a high precision, as well as a good repeatability and reproducibility 
of the assay (table 5). 
 
Table 5. Precision; four different days inter-assay reproducibility and intra-assay 
repeatability. Reprinted from Thålin, C., Daleskog, M., Göransson, S.P. et al. Immunol Res 
(2017) 65: 706. https://doi-org.proxy.kib.ki.se/10.1007/s12026-017-8905-3. © Thålin et al 
2017, with permission under the terms of the Creative Commons Attribution License, open 
access. 
The H3Cit ELISA showed a high precision, with all inter- and intra-assay coefficients of 
variation (CV) < 15%. 
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6.4 CIRCULATING H3CIT IS ELEVATED IN A HUMAN MODEL OF 
ENDOTOXEMIA AND CAN BE DETECTED BOUND TO MICROVESICLES 
(PAPER III) 
In this study rapid and significant elevations of circulating H3Cit following LPS injection in a 
human model of endotoxemia were reported. Results were obtained both by an ELISA and a 
flow cytometric assay, providing two distinct methods to quantify H3Cit in human plasma, 
both readily applicable in a clinical setting. Furthermore, for the first time, H3Cit was shown 
to be detectable bound to MVs. These results imply a novel mechanism by which H3Cit may 
be disseminated throughout the vasculature. 
6.4.1 Circulating H3Cit levels are elevated after LPS injection in a human 
model of endotoxemia and can be measured both by ELISA and by 
flow cytometry.  
The plasma levels of H3Cit were determined by ELISA and flow cytometry in a human 
model of endotoxemia (fig 18). H3Cit levels measured by ELISA displayed a five-fold 
increase in median plasma H3Cit levels 2 hrs after LPS injection (p < 0.001) compared to 
baseline, with a peak at 4 hrs (p < 0.001). The levels decreased between 4 hrs and 7 hrs post 
LPS injection (p < 0.001), but did not yet reach baseline (fig 18A).  
To illustrate whether H3Cit can be measured bound to circulating MVs, we continued by 
performing a flow cytometric assay in order to determine H3Cit-bearing MVs in plasma. A 
slight but significant increase could be seen in H3Cit-bearing MVs 2 hrs post LPS injection 
(p < 0.01) and the median level rose 13-fold by 4 hrs (p < 0.001) compared to baseline. The 
increased levels withstood over the 7 hr study time (fig 18a). 
No significant elevation was seen in the placebo arm neither by using the H3Cit ELISA nor 
the flow cytometry assay. The different dynamics found in the levels of MV-bound H3Cit 
detected by flow cytometry and circulating H3Cit detected by ELISA are shown in figure 
18A, implying a late but sustained elevation of MV-bound H3Cit. 
In order to assess the fraction of H3Cit bound to MVs in the samples, we continued with an 
ELISA-quantification of H3Cit in plasma post high-speed centrifugation, rendering an MV-
enriched pellet and an MV-free supernatant. The level of H3Cit detected in MV-free 
supernatant was roughly 85% of the total amount of H3Cit found in plasma. The amount of 
H3Cit detected in the MV-enriched pellet, i.e. the portion assumed to be bound to MVs, 
accounted for around 10% of the total amount of H3Cit detected in plasma (fig 18B). 
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Figure 18. Circulating levels of H3Cit increased significantly after LPS injection in a 
human model of endotoxemia, comprising both an MV-bound and a non-MV-bound 
portion. Only levels of the LPS arm are plotted in this panel. 
A) H3Cit-bearing MVs detected by flow cytometry (   ) displayed a delayed but sustained 
increase compared to ELISA-detection of total plasma H3Cit levels (---).  
B) ELISA-detected H3Cit levels in MV-free supernatant and MV-enriched pellet 4 hrs post 
LPS injection were approximately 85 % and 10 % respectively of the total amount of H3Cit 
detected in plasma. 
H3Cit; citrullinated histone H3, MVs; microvesicles, ELISA; enzyme-linked immunosorbent 
assay, LPS; lipopolysaccharide, time; change in levels of H3Cit over the study time, groups; 
LPS versus placebo. 
Data are presented as median and IQR. No significant difference was seen if LPS was 
administered at 1st or 2nd study occasion. N=22 for all observations 
 
6.4.2 H3Cit binds selectively to MVs expressing PS in vitro  
To study if H3Cit was able to bind to MVs and to further determine whether this binding is in 
part an attachment between phosfatedyl serine (PS) exposed on MVs and H3Cit, we 
proceeded to incubate in- vitro formed platelet-derived MVs from healthy donor-blood with 
purified H3Cit. By flow cytometry, MVs were first phenotyped based on PS exposure. The 
amount of H3Cit-bearing MVs in each population (PS negative MVs and PS positive MVs) 
was subsequently examined at every concentration of H3Cit incubation (0-1500 ng/ml). 
Results exhibited that H3Cit binds selectively to MVs that are PS positive in a concentration 
dependent way as illustrated in figure 19. No elevation could be seen in H3Cit-bearing MVs 
in the MV population negative for PS. Taken together, these findings indicate a 
binding/complex formation between PS exposed on platelet-derived MVs and H3Cit, 
conceivably through electrostatic forces between the negatively charged PS and the positively 
charged H3Cit.  
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Figure 19. H3Cit binds selectively to MVs positive for PS  
In-vitro generated PS negative and PS positive platelet-derived MVs were incubated in 
various concentrations of purified H3Cit. A significant increase in H3Cit-bearing MVs was 
only seen in the population of MVs positive for PS (* p < 0.05) when incubated in an 
increasing concentration of H3Cit. Results are illustrated as median and range (N=3). MVs = 
microvesicles, H3Cit =citrullinated histone H3, PS = phosfatidylserine. Data are presented as 
median and range. 
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6.4.3 Dynamics of phenotyped MVs after LPS injection 
The levels of platelet-derived MVs increased and peaked prior to neutrophil-derived and 
H3Cit-bearing MVs as shown in figure 20. These dynamics of the MVs corroborate the 
current hypothesis that platelets and neutrophils interact during NETosis [116] in that 
platelets present LPS to the neutrophil in order to induce NETosis [40]. 
 
  
Figure 20. Levels of circulating platelet- and neutrophil-derived MVs, and H3Cit-
bearing MVs after LPS injection 
A) The number of platelet-derived MVs (CD42a+MVs) peaked 2 hrs post LPS injection.      
B-D) In contrast, the number of neutrophil-derived MVs (CD66b+MVs and MPO+MVs) and 
H3Cit-bearing MVs peaked 4-7 hrs following LPS-injection. The placebo arm showed no 
significant dynamics over the study time. MVs; microvesicles; LPS; lipopolysaccharide; 
H3Cit; citrullinated histone H3, time; change in levels of MVs over the study time.  
Data are presented as median and IQR. No significant difference was seen if LPS was 
administered at 1st or 2nd study occasion. N=22 for all observations. 
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Further we phenotyped H3Cit bearing MVs and found that they were derived from both 
platelets (CD42a+) and neutrophils (CD66b+ and MPO+) with the most prominent increase in 
neutrophil derived H3Cit-bearing MVs, especially MPO+MVs bearing H3Cit (fig 21).  
 
 
Figure 21. Phenotypic analyses of MVs indicated that H3Cit-bearing MVs were derived 
from both platelets and neutrophils  
H3Cit-bearing MVs exposed both neutrophil (MPO; A) and CD66b; B) and platelet (CD42a; 
C) specific markers, with the most prominent increases in H3Cit-bearing MVs exposing 
MPO.  
H3Cit; citrullinated histone H3, MVs; microvesicles, LPS; lipopolysaccharide, time; change 
in levels of MVs over the study time; groups; LPS versus placebo. 
Data are presented as median and IQR. No significant difference was seen if LPS was 
administered at 1st or 2nd study occasion. N=22 for all observations. 
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7 DISCUSSION 
Within this thesis we found that iNO+steroid treatment tended to have an organ protective 
effect, mainly in the kidney, although we did not find any grand significances. Moreover, we 
validated an ELISA assay quantifying H3Cit, a biomarker that has revealed great interest in 
the context of sepsis, in human plasma. Using this ELISA assay, we proceeded to 
demonstrate elevations in plasma H3Cit after LPS injection in a human model of 
endotoxemia, supportive of the potential role of H3Cit in sepsis. We furthermore report novel 
data on MV-bound H3Cit, quantifiable by flow cytometry. This not only allows for a rapid 
and robust assessment of in vivo NET formation in a large number of samples, but also 
proposes a possible mechanism by which NET components, such as H3Cit, may be 
disseminated throughout the vasculature. ELISA and flow cytometry are two clinically 
applicable methods that could aid in further research investigating the importance of H3Cit as 
a biomarker in sepsis. Following is a discussion about possible implications of our findings. 
 
7.1 QUANTIFICATION OF H3CIT 
Despite an emerging interest in the field of NETs, there is still a lack of a golden standard 
method or marker to distinguish and quantify NETs in plasma. Consequently, a number of 
markers and methods have been used to establish the presence of NETs [60]. The differences 
in methodologies make it difficult to compare and to interpret results between studies. 
Moreover, as discussed previously, some of these methods are impeded by lack of 
objectivity, quantification and specificity. Paper II proposes an assay allowing for a fast, 
highly objective, specific and reliable quantification of the NET-specific marker H3Cit in 
human plasma. This assay denotes a first step towards a consistency and a specific, as well as 
an objective quantification of NETs in human plasma. 
Although the validation of the H3Cit ELISA displayed a high specificity and reproducibility, 
supported by recent papers implementing the assay [117, 118], there are certain limitations of 
the validation procedure worth noting. Trueness of the concentrations of H3Cit detected in 
plasma could not be assessed in the absence of an established method for comparison or a 
reference analyte of known concentration. Furthermore, the concentration of H3Cit in the 
standard curve is an approximation based on an optimal enzymatic activity of PAD4, 
assuming that all histones are citrullinated. An underestimation of H3Cit-concentrations in 
the samples tested can thereby not be ruled out. Moreover, known concentrations of H3Cit 
spiked in plasma from healthy donors could not be recovered. Presumably, this was due to 
the rapid degradation of free histones in plasma (half-life of 4,6min) [119]. Opposed to free 
histones in plasma, H3Cit quantified in our samples are assumed to be protected by 
surrounding DNA strands, as part of a nucleosome within a NET complex and/or by bondage 
to other protein structures such as MVs. It is thus possible that the H3Cit quantified by the 
H3Cit ELISA constitutes the amount of H3Cit sheltered by the NET complex or other protein 
structures, excluding a potential portion of free H3Cit in plasma. Even though the portion of 
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H3Cit attached to DNA strands in NET complexes is the main point of interest when 
quantifying NETs, the effect of the matrix, however, does impose a limitation to this assay 
validation. 
However, despite these limitations, the methodological validation showed a high specificity 
for H3Cit and allows for a good reproducibility, with CVs all < 15% due to a high stability of 
the custom-made standard. 
We show that H3Cit can bind to MVs, rendering flow cytometry a feasible method for 
quantifying H3Cit. Although we cannot rule out an in vitro electrostatic binding between 
MVs and H3Cit, a recent study by Wang et al [120] indeed report an in vivo complex 
formation between MVs and NETs. This study shows that MVs bind to NETs by means of 
PS on the surface of MVs. Furthermore, the complex of NETs-MVs promoted thrombin 
generation as opposed to NETs not carrying MVs, suggesting that MVs play a critical role in 
NET-induced thrombin generation. Speculating further, MVs may bind to H3Cit entangled in 
NET-complexes, and the MV-H3Cit complex may subsequently detach and be transported 
further downstream. As mentioned before, the portion of circulating H3Cit-bearing MVs 
quantified by flow cytometry in paper III, rose later and remained elevated longer as opposed 
to the total amount of circulating H3Cit, of which the largest part is assumed to be NET-
bound, supporting this hypothesis. H3Cit carried by MVs may thus have a prolonged lifetime 
due to a protective effect of MV-binding after a dismantling of the NET scaffold. 
Interestingly, Ekaney et al [119] demonstrated that histone degradation reached a plateau 
after 30 min, with no further decline during the 6 hr observation. The authors speculate that 
the biological half-life of histones in plasma may be affected by the binding of histone 
fragments to other proteins protecting them from further degradation. MVs may thus serve as 
possible protecting binding proteins. The biological consequences of the H3Cit-MV complex 
remain to be clarified. 
Others have measured NET-components by the means of flow cytometry [121, 122]. These 
studies detect neutrophils positive for NET- associated components. The nature of neutrophils 
though, may pose a potential problem, as they tend to form aggregates making them difficult 
to distinguish as single cells in the flow cytometer [123]. Furthermore, image-based flow 
cytometry, detecting the elongating shape of a decondensed nucleus as a sign of NETosis has 
been proposed [124]. Future studies will determine whether the H3Cit ELISA and/or the flow 
cytometry assay for H3Cit-bearing MVs, could be helpful in a clinical setting determining a 
systemic NET formation in various diseases, such as sepsis. 
 
7.2 EFFECTS OF INO + IV STEROID IN ENDOTOXEMIA 
We could not reproduce the successful data from Da et al in attenuating the multi-organ 
failure in lung, kidney and liver by combining iNO + IV steroid [83], in a similar porcine 
endotoxin model extended from 6 to 30 hrs. One reason could be a lack of power, given the 
greater spread in the data, compared to the study by Da et al. Nevertheless, in spite of the 
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absence of statistical significance, a trend towards a beneficial effect for iNO + IV steroid 
treatment compared to single treatments, was seen for most variables.  
Firstly, there were no deaths in the LPS + iNO+ steroid group as opposed to other LPS 
treated groups, corroborating a protective role of iNO+ steroid treatment. Secondly, there was 
a tendency toward attenuated renal failure, exemplified by the significantly better/higher base 
excess after LPS + iNO + IV steroid treatment compared to after LPS infusion only, 
indicating a preserved buffering function in the kidney. Interestingly, this finding was 
apparent in spite of administration of HES, an IV fluid composed of starch that has since the 
study was performed, been reported to induce renal failure [125]. HES was given to all 
animals receiving LPS with no significant difference in volume between groups. Our data 
signaling a beneficial trend in iNO+steroid attenuation of renal failure is supported by a 
recent publication using a porcine ischemia reperfusion model, reporting that iNO+steroid 
treatment had a beneficial effect by down regulation of renal TLR4 mRNA expression [126]. 
Moreover, iNO has been reported to increase renal filtration [127]. Conversely, iNO treated 
patients were reported to have higher incidence of renal failure in a Cochrane review [128].  
Thirdly, steroid treated groups (LPS + IV steroid and LPS + iNO + IV steroid) tended to 
require less norepinephrine compared to the other LPS treated groups (LPS-only and LPS + 
iNO). This effect could be explained by the enhanced pressor response to norepinephrine 
obtained after administration of steroid in sepsis [108]. Interestingly, the LPS + iNO + IV 
steroid treated pigs only required norepinephrine before treatment was initiated, as opposed to 
the LPS + IV steroid group. This increased hemodynamic stability in the LPS + iNO + IV 
steroid group, could possibly be explained by the LPS-induced down regulation of the 
glucocorticoid receptor [83], which is counteracted by the up regulation of the very same 
receptor by iNO in the LPS + iNO + IV steroid group, a mechanism proposed by Da et al 
[83]. 
INO is known to decrease pulmonary artery hypertension by selective dilatation of 
pulmonary vessels in ventilated areas, thereby increasing the PaO2/FiO2 ratio [98, 99]. We 
did not see a significant improvement in neither of these parameters by administering 30 ppm 
iNO. This could possibly be explained by the fact that some LPS-treated animals did not 
exhibit a PaO2/FiO2 of less than 40 kPa, which is one criterion for an Acute Respiratory 
Distress Syndrome (ARDS) diagnosis [129] and suggest an absence of shunting in the lung, 
thereby leaving little room for iNO to exert its effect. Also, some individuals with pulmonary 
hypertension have been reported to be non-responders to iNO, defined as failure in obtaining 
an improved oxygen tension of at least 20% and/or a decrease in mean pulmonary artery 
pressure of a minimum of 15% [130]. However, a trend towards a decreased MPAP was seen 
in iNO treated groups.  
The iNO treatment in study I aimed primarily at an extra-pulmonary anti-inflammatory 
effect. In ARDS it has been shown that a lower dose of iNO up to 10 ppm, gives a maximally 
improved oxygenation, which again worsens as the dose increases [131]. This is in contrast to 
the dilatory effect on the pulmonary circulation, which is enhanced as the dose is increased. 
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Thus, a controversy appeared at that time: which pharmacodynamic effect should be desired 
for better outcome - best oxygenation or lowest MPAP? In similar, we do not yet know for 
sure which dose of iNO to use in order to reach desired extra-pulmonary effects. Previous 
data reported peripheral effects after administration of iNO 80 ppm during regional NO-
blockade on increased peripheral NO delivery, by nitrosithols [132] and on improved 
intestinal blood flow after ischemia/reperfusion (I/R) in a feline model [133]. Moreover, 40 
ppm iNO, a dose that has been reported to be safe and well-tolerated [134], increased renal 
filtration [127]. The precise dose of iNO 30 ppm, was chosen in accordance with Da et al, as 
was the steroid dose administered, in order to obtain a similar organ preserving effect from 
iNO + IV steroid reported after 3 hrs of LPS infusion [83]. Given the longer study time in 
study I, the 75 mg steroid dose was repeated every 8 hrs, rendering a steroid dose of 9-15 
mg/kg/day, for the pigs included. The steroid dose administered could be compared to the 
proposal from the “surviving sepsis campaign”, recommending a hydrocortisone dose of not 
more than ≈ 3mg/kg/day for vasopressor resistant septic shock [17].  
Finally, the choice of an endotoxin model instead of a real sepsis model is worth discussing: 
Once and again endotoxin was chosen in analogy with Da et al [83] since we wanted to see if 
their results were reproducible even after 30 hrs of LPS infusion, which better agree with the 
clinical reality. However, knowing that endotoxin should rather be considered a model of 
inflammation and not sepsis, we also intended to examine the combination of iNO+steroid on 
another possibly more clinically relevant sepsis model, cecal ligature and puncture (CLP) 
[97]. In the CLP model, the caecum is perforated in anesthetized pigs [135]. However, 
perforation alone did not produce septic shock in our model. Therefore a ligation of the 
mesenteric superior artery producing an I/R reaction was carried out, like in a model earlier 
described [136]. Unfortunately, in our hands, this model proved to be extremely unreliable. 
Indeed, some pigs developed septic shock while others only succumbed to a SIRS reaction. 
This problem has also been described by others [80]. In an article using CLP on a mini-pig 
model the authors discuss that the grade of sepsis could be due to the size of the caecum 
perforation [137]. Possibly, our cecal puncture was too small. We have chosen to report our 
failure to induce a septic shock by CLP and ligation as a short report (yet to be published). 
  
7.3 H3CIT AS A POSSIBLE BIOMARKER EVALUATING TREATMENTS FOR 
MOF? 
The choice of using biomarkers for single organs as outcome variables in paper I, could be 
discussed. Considering that septic shock is a disease affecting the whole body, it would 
probably have been wise to use an outcome variable measuring multiple organ failure. Up to 
date, such a biomarker does not exist, but the Sequential Organ Failure Assessment (SOFA) 
score [21] has been frequently used. However, SOFA score is validated for humans and 
includes the Glasgow Coma Scale (GCS), requiring verbal ability. Consequently SOFA score 
is not applicable to anesthetized pigs, even though it has been used when evaluating organ 
failure in awake pigs [138] and dogs [139]. Modified to evaluate reaction to sounds rather 
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than classic GCS verbal criteria’s, SOFA score seemed to predict mortality also in animals.  
However, a recently validated organ failure score for specific use in critically ill horses, 
performed better in predicting 6-month survival from discharge, compared to scores 
extrapolated from humans [140], indicating a benefit of species-specific organ failure scores. 
In the future it could be worth considering the use of a validated organ score for sedated pigs 
that are frequently used in medical research, in order to assess total organ dysfunction. 
Alternatively, it would be interesting to find a biomarker correlated to MOF that could be 
used as an outcome variable.  
Several studies corroborate the association between high levels of circulating NET 
components, including histones, and their detrimental effects on the host. Components of 
NETs have been associated to activated coagulation [141] and chromatin decondensation 
mediated by PAD4, rendering H3Cit, has been implicated to be vital for thrombus formation 
[142]. Extracellular histones have further been showed to contribute to both micro- and 
macrovascular thrombosis, as well as endothelial and epithelial dysfunction, organ failure and 
tissue injury in murine models of sepsis [44, 45, 143, 144]. These data motivate further 
research on the potential of NET markers, such as H3Cit, as both sepsis-predictive 
biomarkers, as well as possible outcome biomarkers when evaluating treatments in an 
endotoxemic model or septic conditions involving NETosis. 
Notably, H3Cit was not measured in study I. At the time for these experiments, the 
knowledge of H3Cit was not as vast as it is today. Therefore, it is yet to be established if iNO 
or steroid affect H3Cit levels. However, there could be a theoretical possibility that these 
drugs do diminish H3Cit levels since they inhibit the production of e.g. TNF-α and IL-8, two 
known triggers of NETosis [37, 145]. Furthermore, histones [77], as well as MVs [71], 
activate the NFκβ pathway, shown to be inhibited by iNO [105]. INO has further been 
reported to attenuate apoptosis in a rabbit ischemia-reperfusion model [146]. Interestingly, 
this study from 2004 used a technique to detect apoptosis identified as DNA strands on cells, 
and these cells were interpreted as apoptotic. The discovery of NETs may rather propose a 
presence of NETosis.  
It could be speculated whether the drop in leukocyte count 1 hr post LPS injection in the 
human endotoxin model, as well as other studies [94] could reflect NETosis. The same drop 
in white blood cell count was seen in study I, noted 6 hrs after LPS infusion. TNF-α, a known 
trigger of NETosis [145], rising simultaneously with this drop in both the animal- and the 
human endotoxemia-model, corroborates this hypothesis. Interestingly, this drop in white 
blood cell count was more pronounced for the LPS-only and LPS + IV steroid group than in 
the LPS + iNO group and LPS + iNO + IV steroid, conceivably supporting the theory that 
iNO could inhibit NET formation. In addition, steroids have been reported to attenuate both 
I/R-induced kidney injury and sepsis through various mechanisms, comprising glucocorticoid 
receptor activation and protection [147], conceivably enhancing a potential protective effect 
of iNO. 
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Although speculative, H3Cit may be a reasonable outcome biomarker evaluating the effects 
by iNO + IV steroid on MOF in a future endotoxemia study. 
 
7.4 H3CIT AS A TARGET FOR INTERVENTION 
In light of the detrimental effects of NETs, promising NET inhibiting agents, such as PAD-
inhibitors [64, 148, 149] and NET degrading agents such as DNase [45, 150, 151] have been 
evaluated in murine models, appearing to suppress circulating H3Cit levels with improved 
survival [148, 149, 152]. 
Up to date, it has not been sufficiently validated what would be most beneficial; to 
decompose existing NETs, or to inhibit NETosis. It is however, conceivable that the choice of 
drug could be dependent of timing during sepsis progression. Consequently, a PAD4 inhibitor 
could slow down the NET formation at an early stage, whereas DNase could possibly be 
useful at a later state when NETs are already abundant.  
Notably, several authors have discussed the balance between the antimicrobial and cytotoxic 
effects of NETs as a preservation of NETosis, and possible favorable effects thereof in the 
early stage of sepsis may be necessary to combat the infection [45, 153]. Reflecting this 
hypothesis, it could be of value to determine a “cut-off” level for when NETs become 
detrimental and could benefit from being inhibited. ELISA- and/or flow cytometry 
quantification of circulating H3Cit, could be useful methods in deciding when to intervene 
with NET production or to follow disease progression. Interestingly, Biron et al found that 
PAD4 deficient mice had impaired NET formation, despite similar amount of neutrophil 
infiltration, in kidney and lung. These PAD4-deficient mice unable to release NETs, also 
displayed preserved renal function compared to wild type (WT) mice [154]. Furthermore, 
another study using PAD4 deficient mice, showed that these mice fared better compared to 
WT mice after infection with influenza A despite the absence of NET formation, suggesting 
that NET formation is dispensable for immunity against influenza infection [155]. In the 
same manner, Martinod et al showed that PAD4 deficient mice subjected to polymicrobial 
sepsis had comparable survival to WT mice. Interestingly, PAD4-deficient mice were further 
partially protected from LPS-induced shock with a reduced inflammatory and 
hypercoagulable/ prothrombotic state, compared to PAD4 WT mice [156]. Thereby, it can be 
speculated if NET function even at an early stage of sepsis and endotoxemia, is redundant. 
In study I, iNO + IV steroid treatment was initiated when endotoxemia had already been 
persistent for 3 hrs. The time point for treatment start was decided in analogy with the study 
from Da et al [83] and was chosen in order to mimic the clinical reality in which sepsis 
patients present to the ICU after the onset of septic shock. Considering the hypothesis that 
iNO + steroid inhibit NETosis rather than degrade already existing NETs, perhaps a better 
effect could have been achieved if iNO+steroid was initiated earlier, possibly even before 
endotoxin infusion. The idea of prophylactically administrated iNO for better anti-
inflammatory outcome is corroborated by an I/R model of anesthetized patients undergoing 
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knee surgery. Patients exposed to iNO at 80 ppm 30 min before and during tourniquet 
application, displayed significantly reduced inflammation [100]. The reduced inflammation 
could however not be shown in a similar study, in patients receiving spinal anesthesia, due to 
lack of inflammatory response [157]. Lang et al showed that preoperative administration of 
80 ppm iNO improved liver function after transplantation and also decreased hospital length 
of stay [158]. The same dose given before and during myocardial ischemia and reperfusion in 
pigs, significantly reduced infarction size and improved microvascular perfusion, decreased 
leukocyte infiltration and decreased cardiomyocyte apoptosis [159]. Further, prophylactically 
administered iNO 80 ppm + IV steroid also showed a beneficial effect in an I/R model in pigs 
by diminishing the expression of messenger RNA TLR4 in kidney [126]. On the other hand, 
Da et al found that iNO + IV steroid had an organ protecting effect despite being 
administered 3 hrs post start of LPS infusion.  
One hypothesis to the success of Da et al despite a relatively late administration of 
iNO+steroid, could be that LPS, being a potent trigger of NETosis [37], induces a continuous 
NETosis when given as an infusion until a possible rate-limiting step, as discussed in a 
previous article [153]. The authors propose that a limiting step in NETosis could be platelet 
depletion. In our porcine endotoxin model we found a significant fall in platelets after 24 hrs 
compared to baseline, possibly resulting in a decreased NET formation around this time 
point, which would be conceivable considering the pivotal role of platelets in LPS-induced 
NETosis [40]. The fall in platelet count for the healthy control group, could be due to the 
precence of the pulmonary arthery catheter (PAC). The use of PAC and the association to 
thrombocytopenia has been reported previously and is believed to be due to an increased 
consumption of platelets [160, 161] after microaggregation on the catheter with a subsequent 
phagocytosis by macrophages [162].  
Interestingly, in the human model of endotoxemia, plasma levels of TNF-α peaked 1.5 hrs 
post LPS injection, whereas plasma H3Cit levels detected by ELISA peaked 3 hrs post LPS 
injection. TNF-α has been shown to trigger NETosis, and displayed a later rise at 6 hrs post 
LPS infusion in the porcine model of endotoxemia. A hypothetical NET burden may 
therefore have occurred later in the porcine model of endotoxemia and thus partly have 
contributed to multi-organ damage 12 hrs post LPS infusion. This hypothesis is supported by 
the increase in creatinine seen at this time point. 
The potential of NET inhibitors to alleviate damaging NET-induced effects in endotoxemia 
and sepsis remains to be elucidated, as does the optimal balance between the antimicrobial 
and cytotoxic effects of NETs. 
 
7.5 H3CIT AS A BIOMARKER FOR DIAGNOSES OF SEPTIC SHOCK 
In the clinical setting of the emergency room or the intensive care unit, the appearance of low 
blood pressure could be a question of debate. Differential diagnoses could be heart failure, 
dehydration, hemorrhage, septic shock or possibly deep sedation among others. Although 
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H3Cit levels have been shown to be elevated in non-infectious conditions such as cancer 
[117] and thromboembolism [163], these diagnoses rarely go with shock. Studies have shown 
that H3Cit levels are not elevated in non-septic shock states, but in endotoxic and septic 
shock [149, 164], thereby making the use of H3Cit a possible diagnosing tool for septic 
shock. 
Nevertheless, the specific pathogen causing the infection may be crucial in selecting a 
suitable biomarker to diagnose sepsis, since different pathogens could affect the immune 
system differently [165]. H3Cit may be a promising biomarker for sepsis caused by 
pathogens described to induce NET formation, such as E. coli, Staphylococcus aureus, Group 
A streptococci and Candida albicans [37], but it remains elusive whether all microbes induce 
NET formation. Consequently, H3Cit as well as other NET-components, could be pathogen- 
dependent biomarkers, and their role in a universal sepsis-screening setting is yet to be 
established  
 
7.6 ROLE OF H3CIT AS A PREDICTIVE BIOMARKER FOR SEPSIS 
As stated above, increased levels of H3Cit and other NET-components have been correlated 
to a higher SOFA score in a cross-sectional study of sepsis patients [45]. However it remains 
elusive if plasma levels of H3Cit could actually predict the severity of MOF associated with 
septic shock. Early elevations of plasma cfDNA have been detected at admission in trauma 
[166] and burn patients [167]. These levels increased further in patients developing septic 
shock including MOF. However, considering that cfDNA is elevated in tissue damage [61], it 
is not clear if the early rise in circulating cfDNA in these studies reflect NETosis or rather 
cellular damage from the trauma. In the study of multiple trauma patients by Margraf et al, 
high levels of cfDNA were associated with subsequent sepsis, MOF and death, but the origin 
of cfDNA can still be debated. Interestingly, the results from Hampson et al [164], showed 
early rises in cfDNA in burn patients, as opposed to plasma H3Cit detected by western blot, 
which rose only during septic episodes thereafter. These data might suggest that H3Cit may 
be a more specific marker for predicting a second hit with sepsis compared to cfDNA, in burn 
and possibly trauma patients.  
Pan et al showed elevated plasma H3Cit levels as early as 30 min after LPS injection. 
Moreover, H3Cit was found to be more reactive to endotoxemia than the inflammatory 
cytokines IL-1β and IL-6 as well as the clinically employed septic biomarker procalcitonin 
[149]. CRP also increased relatively late, at 6 hrs after endotoxemia injection in humans [94], 
which was the reason of not measuring CRP in our 7 hrs human endotoxemia model. These 
findings could suggest that H3Cit might have a place in predicting sepsis before the onset of 
symptoms, as well as before increased levels of procalcitonin and CRP. Septic shock may 
develop quickly urging the need for early and reliable biomarkers. Flow cytometry may, in 
this respect be favorable over ELISA methodology, rendering quick results within the hour, 
as opposed to the ELISA assay, which takes several hours. Notably, our first sample analysed 
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for H3Cit after LPS injection was at 2 hours in the human endotoxin model of paper III, i.e. 
after the onset of clinical symptoms, which appeared 1hr post LPS injection, limiting our 
ability to assess plasma H3Cit as an early blood biomarker. The levels of H3Cit+MVs, 
although significantly elevated at 2 hrs compared to baseline, did however, not show the 
same dramatic early elevation as H3Cit measured with ELISA at the same time point, 
indicating that MV-bound H3Cit may rise later than H3Cit anlysed by ELISA, that could 
possibly be NET-bound. 
Delabranche et al have suggested endothelial derived MVs as a predictive biomarker of 
disseminated intravascular coagulation (DIC) [168]. The authors speculate about MVs as a 
more clinically relevant biomarker of early DIC, being more easily measured when 
circulating in blood compared to NETs that could be trapped in thrombi. Our data illustrating 
that the peak of H3cit measured by ELISA precedes the predominant levels of MVs, might 
contradict this theory. Further, the clear rise in platelet-derived (CD42+) MVs, preceding the 
peak of H3Cit-bearing MVs in paper III, raises the question as to whether platelet- derived 
MVs may be an earlier biomarker, possibly mirroring a subsequent NET-formation. This 
hypothesis is corroborated by the role of platelets in NETosis [40] and is further supported by 
data reporting that a decreased septic-release of MVs by inhibition of the NFκβ pathway, 
resulted in attenuated inflammatory- and DIC processes, as well as organ dysfunction, and an 
increased survival after CLP induced sepsis [73]. Nevertheless, it remains elusive whether the 
NFκβ-inhibition also affects NETosis directly.  In contrast, Soriano et al showed that platelet 
and leukocyte derived MVs were inversely correlated with SOFA score [71]. Inconsistencies 
concerning the role of MVs in sepsis could possibly be explained by different profile-
variations of MVs depending of the source of infection [165], which corroborate the above-
discussed hypothesis about pathogen specific biomarkers. 
  
7.7 PROBLEMS AND OTHER FUTURE APPROACHES OF BIOMARKERS 
The theory about different pathogen dependent immune-profiles reinforces the commonly 
discussed thesis that sepsis cannot be predicted by one single-, but rather a combination of 
different biomarkers. Conceivably, H3Cit could play a role in such a battery. Finding new 
reliable biomarkers for septic shock associated with outcome could not only predict the 
disease course of sepsis, but also advance the medical research in evaluating new treatments. 
At the same time, one has to be humble before the complexity of the sepsis pathogenesis. 
Targeting one single biomarker may not be a viable approach for treating an intricate 
inflammatory response to diverse pathogens. Similarly, timing might be crucial considering 
that cytokines and immune cells play both protective and pathogenic roles in sepsis.  
Lately, so called Omics, combining quantifications of e.g. transcription factors like 
messenger RNA, that translate into different molecules included in the pathogeneses of sepsis 
have rendered some interest. Omics have been studied in order to predict the outcome of 
sepsis [15]. Speculating widely, the Omics technique could possibly be an earlier way to 
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detect deleterious components in the sepsis pathology, conceivably making them possible to 
target before the actual NET formation. Considering the genetic predisposition in developing 
septic shock, it could further be speculated if a certain genetic defect could be detected by 
Omics, thereby possibly identifying individuals that experience a higher risk for sepsis with 
MOF.  
Conclusively, summing up the results from this thesis, as well as other reports from the 
literature, circulating H3Cit may have a potential role as a biomarker in endotoxemia and 
sepsis, both by diagnosing as well as predicting outcome. However, in order to decide the 
value of circulating H3Cit as a biomarker in sepsis, further research is warranted in real-life 
clinical settings. For this purpose, the H3Cit ELISA presented in paper II and the flow 
cytometric assay detecting H3Cit-bearing MVs presented in paper III may be helpful. 
Moreover, further research will reveal if H3Cit could be a target of intervention in the future, 
possibly even by iNO. Meanwhile, it would be interesting to validate H3Cit as a marker of 
MOF in endotoxemia- or other sepsis models, when studying potential sepsis treatments. 
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8 CONCLUSIONS 
 
• A combination of iNO+steroid tends to attenutate the multi-organ failure 
associated with endotoxin stimulation in pigs, although no clear significances 
between LPS + iNO + IV steroid compared to LPS-only could be proven in our 
material. (Paper I) 
 
• In order to prove significances when studying MOF in endotoxic and possibly septic 
shock, an outcome varible weighing in the total organ failure should be used, 
rather than just one single organ specific biomarker (e.g. creatinine, blood pressure, 
mean pulmonary artery pressure, platelets, base excess). As such, scoring systems like 
SOFA score apply. (Paper I) 
 
• Levels of H3Cit, a NET specific marker, can be reliably quantified in human 
plasma by means of a novel enzyme-linked immunosorbent assay (ELISA), allowing 
for a high precision, stability and specificity. (Paper II) 
 
• Circulating H3Cit is elevated in humans after endotoxin injection and can be 
detected by both an ELISA and bound to microvesicles (MVs), by flow 
cytometry. The MV-bound portion of H3Cit seems to remain elevated longer than the 
ELISA-detected portion, assumed to be bound to NETs. This suggests that H3Cit may 
be disseminated throughout the vasculature bound to, and possibly protected, by 
MVs. (Paper III) 
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9 SVENSK SAMMANFATTNING 
9.1 BAKGRUND 
Den här avhandlingen behandlar ämnet svår blodförgiftning, som i vissa fall kan drabba hela 
kroppen genom kraftig inflammation. Det ger upphov till organsvikt. Tillståndet har en hög 
dödlighet på ca 25-30%, som kan minskas förutsatt att diagnosen ställs tidigt i kombination 
med att rätt behandling, t.ex. antibiotika och intensivvård kan sättas in snabbt. Svår 
blodförgiftning är inte lätt att diagnostisera korrekt och tidigt, då vi idag inte har specifika 
blodprover för att fastställa sjukdomen. Troligen skulle man också kunna sänka dödligheten i 
svår blodförgiftning om det gick att minska den organsvikt som sjukdomen medför. Någon 
medicin för att minska organsvikten finns inte idag. 
 
9.2 SYFTEN 
I första delarbetet ville vi studera om två i Sverige redan registrerade läkemedel, inhalerat 
kväveoxid (iNO) och kortison i kombination, kan minska graden av organsvikt som 
uppkommer i samband med svår sepsis. Vidare ville vi mäta hur proteinet citrullinerat 
histon H3 (H3Cit) i blodet reagerar vid inflammation (delarbete 3). H3Cit har de senaste 
åren rapporterats vara en blodmarkör som man skulle kunna mäta, både för att eventuellt 
kunna avgöra vem som kommer drabbas av svår blodförgiftning, samt för att kunna ställa 
diagnosen svår blodförgiftning. Det finns dessutom data i litteraturen som indikerar att H3Cit 
i sig har en ”giftverkan” och att behandling inriktad på att hämma nivåerna av H3Cit i blodet 
skulle kunna minska skadliga effekter av blodförgiftning på kroppen. H3Cit har däremot varit 
svårstuderat eftersom det inte funnits någon bevisat fungerande metod för att mäta H3Cit i 
blodet. För att kunna studera H3Cit på ett bra sätt utvecklades därför först en metod för att 
kunna mäta det i human plasma (delarbete 2). För att bättre förstå vilken betydelse H3Cit har 
för sjukdomsförloppet vid blodförgiftning, är det viktigt att veta på vilket sätt H3Cit 
cirkulerar i kroppen. Vi ville därför se om det kunde vara bundet till en annan partikel i 
blodet s.k. mikrovesiklar (delarbete 3), som har visats kunna transportera olika former av 
molekyler genom kroppen. Mikrovesiklar är som ett ”kladdigt damm” som frisätts vid 
blodförgiftning bl.a. från immunförsvarets celler.  
 
9.3 METODER  
Utvärderingen av iNO + kortisons effekt gjordes på sövda grisar eftersom man inte får 
studera nya behandlingar direkt på människor. Metoden för att mäta H3Cit är en ELISA-
baserad metod, och utvecklades i enighet med bestämda riktlinjer. ELISAn användes sedan 
för att se hur H3Cit rör sig över tid vid inflammation. Detta möjliggjordes genom att ett 
övergående, lättare inflammations-tillstånd (feber, muskel- och huvudvärk) skapades hos 
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friska försökspersoner. För att mäta om H3Cit kunde binda till mikrovesiklar användes 
metoden flödescytometri. 
Forskningen i avhandlingsarbetet är experimentell. Experimentell forskning är viktig 
eftersom patienter med blodförgiftning inom sjukvården utgör en mycket blandad grupp. 
Patienterna kommer t.ex. till sjukhus i olika sjukdomsstadier och är infekterade med olika 
bakterier, bara för att nämna några faktorer. Via experimentell forskning kan också kroppens 
svar på inflammation studeras på ett mer standardiserat sätt. På så vis blir det lättare att tolka 
de provsvar man får från sjuka patienter i framtida studier. 
 
9.4 RESULTAT  
Vi hittade inte statistiskt signifikanta skillnader med mindre organsvikt för 
behandlingsgruppen som fått iNO + kortison jämfört med de sjuka grisar som inte fått 
behandling. Däremot kunde man se en tendens till bl.a. minskad njurskada hos 
iNO+kortison gruppen. Vidare kunde cirkulerande H3Cit nivåer hos människa med 
lättare inflammations-tillstånd mätas med den i delarbete 2 utvecklade ELISA metoden. 
Med flödescytometri kunde vi även påvisa att H3Cit binder till mikrovesiklar 
 
9.5 SLUTSATSER  
INO+kortison visar en tendens till att skydda kroppens organ vid den svåra inflammation 
som sker vid blodförgiftning i studien på sövda grisar. Kunskap om mer exakta 
verkningsmekanismer och optimala doser av dessa läkemedel är däremot fortsatt bristfällig. 
Skyddseffekterna av kombinationsbehandlingen iNO + kortison är för svaga för att på basen 
av fynden i den här avhandlingen föreslå behandlingsförsök på människa med 
blodförgiftning. Vidare så kan H3Cit, vilket föreslagits som en viktig parameter vid svår 
sepsis, mätas tillförlitligt i blod med två oberoende metoder vilka båda är möjliga att 
använda i klinisk praxis. Våra resultat talar också för att H3Cit kan transporteras i 
blodcirkulationen bundet till mikrovesikler. Betydelsen av mikrovesikelbundet H3Cit är 
däremot inte klarlagd. 
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